Â Â UNITED STATESÂ SECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549Â FORM 6-KÂ REPORT OF FOREIGNPRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934Â For the month of August 2024Â Â Commission File Number: 001-41982Â Auna S.A.(Exact name of registrant as specified in itscharter)Â â€Ž 6, rue Jean MonnetL-2180 LuxembourgGrand Duchy of Luxembourgâ€Ž+51 1-205-3500â€Ž(Address of principal executive office)Â Indicate by check mark whether the registrant filesor will file annual reports under cover of FormÂ 20-F or Form 40-F:Â Form 20-F XÂ Â Form 40-F Â Â Â Â Â Â Â Â Â Â TABLE OF CONTENTSÂ EXHIBIT Â 99.1 Press release dated August 21, 2024 â€“ Auna Announces 2Q24 Financial Results 99.2 Unaudited Condensed Consolidated Interim Financial Statements as of and for the three-month and six-month periods ended June 30, 2024 Â Â Â SIGNATUREÂ Pursuant to the requirements of the SecuritiesExchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.Â Â Â Auna S.A. Â Â Â Â Â Â Â Â Â By: /s/ Gisele Remy Â Â Â Â Name: Gisele Remy Â Â Â Â Title: Chief Financial Officer Date: August 21, 2024Â Â Â Â Â Exhibit 99.1Â AunaAnnounces 2Q24 Financial ResultsÂ Adjusted EBITDA increases 31%YoY, consolidating strong results Â OncoMexico launched in MonterreyÂ Luxembourg, August 21, 2024 â€“ Auna (NYSE:AUNA) (â€œAunaâ€ or the â€œCompanyâ€), a leading healthcare platform in Latin America with operations in Mexico,Colombia and Peru, today announced unaudited financial results for the second quarter ended June 30, 2024 (â€œsecond quarter 2024â€or â€œ2Q24â€). Financial results are expressed in Peruvian Soles (â€œS/â€ or PENâ€) and are presented in accordancewith International Financial Reporting Standards (â€œIFRSâ€), unless otherwise noted.Â 2Q24 Consolidated HighlightsÂ â—Consolidated Revenue increased 18% YoY to S/1,120 millionÂ â—Operating profit increased 34% YoY to S/183 millionÂ â—Adjusted EBITDA increased 31% YoY to S/248 million, equivalent to 25% FXN (Foreign Exchange Neutral)Â â—Adjusted EBITDA Margin of 22.1%, up 2.0 p.p. YoY and 0.5 p.p. YTDÂ â—Leverage ratio improved to 4.13x from 4.46x in 1Q24 and 4.89x in 2Q23Â Recent EventÂ On July 1, 2024, Auna announced the launch of OncoMexico,the countryâ€™s first integrated oncology insurance, in Monterrey. The pilot phase during 2024 will develop and confirm the capabilitiesneeded for full deployment in 2025. OncoMexico offers access to prevention, early detection, and treatment of cancer, the third leadingcause of death in Mexico. OncoMexico is the first step toward replicating in Mexico the vertically integrated healthcare model that Aunasuccessfully operates in Peru.Â Message from Aunaâ€™s ExecutiveChairman and PresidentÂ Second quarter results affirm again the effectivenessof our business model and how increased scale and maturity drive incremental value throughout our platforms of care. During the quarterwe gained momentum, with Adjusted EBITDA increasing 31% YoY, or 25% FXN YoY, and keeping us on track to deliver at least 20% FXN AdjustedEBITDA growth this year. Our strong quarterly performance was achieved despite additional investments made to implement the AunaWay inMonterrey, where we continue to make headway recruiting the right physicians and expanding our delivery of high-complexity care. As morephysicians recognize the many distinct advantages of the AunaWay and join our team, we are beginning to see increases in doctor productivity.New physicianÂ 1Â Â recruitment and compensation models are producinggrowth in a number of high-complexity services. During the remainder of the year and into 2025 we expect to harvest our efforts to raiseoccupancy levels in Mexico, particularly occupancy related to high-complexity care. All of this is a deliberate and gradual process thatresults from fostering our unique culture of patient care in Monterrey.Â Both our Peruvian and Colombian operations continuedto perform well during the quarter, further validating our scalable business model and growth strategy. Given the increasing predictabilityof our diversified regional platformâ€™s performance, we remain confident in our plan to achieve similar performance levels in Mexico.Â Our payors are also integral to succeeding in Mexico,many of which are already familiar with Aunaâ€™s high standards of care. We are offering them tailored products and bundled servicessimilar to those in Peru and Colombia, where we have forged many win-win partnerships.Â We are very proud to have launched OncoMexico.Leveraging our 35 years of experience in integrated oncological services and AunaSegurosâ€™ (previously Dentegra) strong and extensivedistribution platform in Mexico, we will gradually roll out OncoMexico, the countryâ€™s first integrated cancer insurance plan. Weintend to replicate our past success, including the goal of operating with the same long-term Medical Loss Ratio (â€œMLRâ€) andhigh standards of OncoSalud. During the rest of this year, we will establish the necessary capabilities to roll-out OncoMexico at scalein 2025, including commercial, clinical and risk-underwriting operations, among others.Â Looking ahead, we remain excited about Aunaâ€™snear and long-term growth opportunities, particularly given that we are in the relatively early stages of penetrating Spanish-speakingLatin Americaâ€™s fragmented and underserved healthcare market. Through our unique operating model and scalable regional platform,we will continue to disrupt, modernize, and increase access to integrated healthcare in the region, always with the aim of providing highvalue to our patients, their families, Auna staff, and shareholders.Â Overview of 2Q24 Consolidated ResultsÂ Consolidated revenues increased18% YoY to S/1,120 million, or 12.5% FXN, as a result of Aunaâ€™s business mix, with revenues increasing 15% and 18% FXN in Peru andColombia, respectively. In Mexico, revenues increased 3% FXN, reflecting an improved service mix through the implementation of the AunaWay.Â Aunaâ€™s Peruvian operation continuesto outperform, demonstrating again the success of the Companyâ€™s vertically integrated business model when operating at scale.Â 2Â Â Adjusted EBITDA increased 31%YoY, or S/58 million, to S/248 million, or 25% on an FXN basis, with the corresponding margin expanding to 22.1% on solid revenue growthand increasing efficiencies across local and regional levels as the Company continues to capture synergies and streamline processes. Operatingprofit increased 34% YoY, mainly due to a 19% increase in gross profit.Â Net finance costs were S/182 million.When excluding FX effects, net interest expenses would have been S/133 million, an increase of 5% versus 2Q23. These FX effects includea negative non-cash accounting FX expense of S/49 million, corresponding mainly to the movement of the Peruvian Sol below the floor ofUSD/PEN hedges.Â Net Income was S/8 million in2Q24, compared to a Net loss of S/8 million in 1Q24 and Net income of S/23 million in 2Q23. The increases in Operating profit and deferredtax benefits versus 2Q23 were offset by the abovementioned negative FX effect.Â Adjusted Net Income was S/13 millionin 2Q24, lower than S/36 million in 2Q23 and S/22 million in 1Q24, mainly due to the negative non-cash FX effect explained above. On aquarterly per share basis, Auna reported Net Income of S/0.05 and Adjusted Net Income of S/0.12, both based on a weighted average numberof outstanding shares of 73,970,299, which includes a stock-based payment for 52,722 shares granted but not yet issued.Â Business performanceÂ HEALTHCARE SERVICESMEXICOÂ (Explanations of variances arein local currency)Â Aunaâ€²s Healthcare Services and AunaSegurosoperations in Mexico accounted for 27% of consolidated revenues and 40% of Adjusted EBITDA.Â (Figures in millions of Solesand millions of US Dollars, unless expressed otherwise)Â Â Â Â Â Â Â Â Î” 2Q'24 vs 2Q'23 Î” YTD'24 vs YTD'23 Healthcare Services MexicoKey Operating Metrics Â Â 2Q'24 (USD) 2Q'24 YTD'24 Â As Reported Â Local Currency As Reported Â Local Currency Beds # Â Â 708 708 Â 0% Â Â 0% Â Â Surgeries # (000) Â Â 5 10 Â 6% Â Â 2% Â Â Emergency treatments # (000) Â Â 9

19 Â -9% Â Â -1% Â Â Occupancy (operating capacity) % Â Â Â 62.1% Â Â Â Â -1.4 p.p. Â Â Occupancy (total capacity) % Â Â Â 41.3% Â Â Â Â -1.0 p.p. Â Â Key Financial Metrics Â Â Â Â Â Â Â Â Â Â Â Â Revenue Â Â 79 302 611 Â 7% Â 3% 11% Â 4% Segment Adjusted EBITDA Â Â 26 100 204 Â 4% Â 0% -3% Â -8% Segment Adjusted EBITDA margin % Â Â 33.1% 33.4% Â -1.2 p.p. Â Â -4.5 p.p. Â Â Â RevenueÂ Revenue in Mexico increased 3% YoY, primarily drivenby an increase in the number of surgeries, aligned with the Companyâ€™s plans to grow high-complexity procedures.Â 3Â Â Aunaremains focused on increasing growth and profitability in Mexico by raising occupancy levels and further increasing the delivery of high-complexityservices.Â To achieve these goals, the Company is making progress with two parallel initiatives:Â (i)a physician relationship and incentive model focused on recruiting doctors in higher-complexity specialties, and on retaining currentdoctors and improving their productivity by offering them competitive incentives, and; (ii) tailor-made products and programs for payors,that are aimed at increasing referrals to Aunaâ€™s network.Â These initiatives are expected to have a greaterimpact on Mexicoâ€²s revenue and profitability in the second half of 2024 and in 2025. However, the Company is already experiencingincreases in doctor productivity under the new physician relationship and incentive model, with higher volumes of certain high-complexityservices, mainly surgeries, in 2Q24.Â Adjusted EBITDAÂ Adjusted EBITDA in Mexico was flat YoY with a healthymargin of 33.1% despite YoY increases in operating costs and SG&A incurred to strengthen local and regional capabilities.Â PERU OPERATIONS: HEALTHCARESERVICES PERU AND ONCOSALUD PERUÂ Aunaâ€²s Healthcare Services and OncoSaludPeru (Aunaâ€™s Healthcare plans in Peru) accounted for 39% of consolidated revenues and 38% of Adjusted EBITDA.Â (Figures in millions of Solesand millions of US Dollars, unless expressed otherwise)Â Healthcare Services Peru and Oncosalud PeruKey Financial Metrics Â Â 2Q'24 (USD) 2Q'24 YTD'24 Â Î" 2Q'24 vs 2Q'23 Î" YTD'24 vs YTD'23 Revenue Â Â 115 441 859 Â 15% 14% Healthcare Services Peru Â Â 67 255 496 Â 18% 16% Oncosalud Peru Â Â 70 269 522 Â 17% 16% Holding and Eliminations (*) Â Â Â (83) (159) Â 30% 26% Consolidated Peru Adjusted EBITDA Â Â 24 93 179 Â 96% 65% Healthcare Services Peru Â Â 10 40 77 Â 318% 146% Oncosalud Peru Â Â 14 54 102 Â 40% 32% Consolidated Peru Adj. EBITDA margin % Â Â 21.2% 20.8% Â 8.7 p.p. 6.4 p.p. Healthcare Services Peru Â Â Â 15.6% 15.5% Â 11.2 p.p. 8.2 p.p. Oncosalud Peru Â Â Â 19.9% 19.5% Â 3.3 p.p. 2.4 p.p. Â Â Â Â Â Â Â Â Â Â (*) Relates to intersegment revenue elimination. Â Â Â Â Â Â Â Â Â 4Â Â Â Healthcare Services PeruKey Operating Metrics Â Â 2Q'24 (USD) 2Q'24 YTD'24 Â Î" 2Q'24 vs 2Q'23 Î" YTD'24 vs YTD'23 Beds # Â Â 375 375 Â 0% 0% Surgeries # (000) Â Â 5 10 Â 1% 2% Emergency treatments # (000) Â Â 47 86 Â -9% -4% Occupancy (operating capacity) % Â Â Â 82.2% Â Â 5.9 p.p. Occupancy (total capacity) % Â Â Â 71.9% Â Â 5.8 p.p. Key Financial Metrics Â Â Â Â Â Â Â Â Revenue Â Â 67 255 496 Â 18% 16% External revenues Â Â 48 183 357 Â 12% 11% Intercompany revenue Â Â 19 72 139 Â 35% 31% Segment Adjusted EBITDA Â Â 10 40 77 Â 318% 146% Segment Adjusted EBITDA margin % Â Â 15.6% 15.5% Â 11.2 p.p. 8.2 p.p. Â Healthcare Plans PeruKey Operating Metrics Â Â 2Q'24 (USD) 2Q'24 YTD'24 Â Î" 2Q'24 vs 2Q'23 Î" YTD'24 vs YTD'23 Plan memberships # (000) Â Â 1,263 1,263 Â 5% 5% Oncological Plans # (000) Â Â 972 972 Â 3% 3% Average monthly revenue per plan membership Â Â 15.57 60.60 59.64 Â 2% 3% Preventive check-ups # (000) Â Â 25 52 Â -24% -23% Patients treated # (000) Â Â 13 45 Â -3% 3% MLR % Â Â Â 58.6% Â Â 7.4 p.p. Oncological Plans % Â Â Â 54.7% Â Â 5.2 p.p. Key FinancialÂ Metrics Â Â Â Â Â Â Â Â Revenue Â Â 70 269 522 Â 17% 16% External revenues Â Â 67 258 502 Â 17% 16% Intercompany revenue Â Â 3 11 20 Â 7% 2% Segment Adjusted EBITDA Â Â 14 54 102 Â 40% 32% Segment Adjusted EBITDA margin % Â Â 19.9% 19.5% Â 3.3 p.p. 2.4 p.p. Â Consolidated Revenue from Peru increased15% YoY, or S/57 million, to S/441 million. This growth was mainly due to a 5% increase in memberships in the Healthcare Plans businessand an 18% revenue increase in the Healthcare Services business, mainly due to higher occupancy and an improvement in the mix of servicesand specialties as the Company continues to focus on high-complexity care.Â 5Â Â Consolidated Adjusted EBITDA in Peru almostdoubled YoY, growing from S/46 million to S/93 million, with the margin expanding 8.7 p.p. to 21.2%. Since 2021, Auna has implementedseveral initiatives to improve the profitability of its operations in Peru, which continue to positively impact performance. These measureshave resulted in sustained growth in plan memberships, occupancy at the Companyâ€™s healthcare facilities, and high-complexity services.The continuous implementation of an effective pricing strategy across services and segments also contributed to improved profitability.In addition to revenue growth, improved efficiencies reduced SG&A by 6% YoY. The oncological MLR of the Healthcare Plans businessin Peru was 54.7% as of June 30, 2024. MLR increased mainly due to an increase in intercompany fees between Aunaâ€™s OncoSalud insurancecompany and its integrated oncology hospitals.Â HEALTHCARE SERVICES COLOMBIAÂ (variance explanations are inlocal currency)Â Aunaâ€²s Healthcare services operations inColombia accounted for 34% of consolidated revenues and 23% of Adjusted EBITDA.Â (Figures in millions of Solesand millions of US Dollars, unless expressed otherwise)Â Â Â Â Â Â Â Â Î" 2Q'24 vs 2Q'23 Î" YTD'24 vs YTD'23 Healthcare Services ColombiaKey Operating Metrics Â Â 2Q'24 (USD) 2Q'24 YTD'24 Â As Reported Â Local Currency As Reported Â Local Currency Beds # Â Â 1,116 1,116 Â 1% Â Â 1% Â Â Surgeries # (000) Â Â 12 24 Â -2% Â Â -1% Â Â Emergency treatments # (000) Â Â 34 71 Â 17% Â Â 4% Â Â Occupancy (operating capacity) % Â Â Â 87.2% Â Â Â Â 2.1 p.p Â Â Occupancy (total capacity) % Â Â Â 80.6% Â Â Â Â 6.0 p.p Â Â Key Financial Metrics Â Â Â Â Â Â Â Â Â Â Â Â Revenue Â Â 99 378 727 Â 34% Â 18% 36% Â 17% Segment Adjusted EBITDA Â Â 15 58 108 Â 25% Â 10% 31% Â 13% Segment Adjusted EBITDA margin % Â Â 15.3% 14.8% Â -1.1 p.p Â Â -0.5 p.p. Â Â Â Revenue Â Revenue increased 18% YoY, primarily driven byan improvement in the revenue mix as well as an increase in occupancy.Â Adjusted EBITDAÂ Adjusted EBITDA in Colombia increased 10% YoY,with a margin decrease of 1.1 p.p. to 15.3%, mainly attributable to an increase in the impairment for doubtful accounts, given the currentmarket environment in Colombia.Â 6Â Â Balance Sheet & Cash FlowÂ Consolidated DebtÂ (Figures in millions of Solesand millions of US Dollars, unless expressed otherwise)Â Â Â Jun-24 (USD) Jun-24 Dec-23 Jun-23 Â Î" Jun-24 vs Â Â Â Dec-23 Jun-23 (+) Loans and borrowings Â 987 3,780 3,762 3,410 Â 0% 11% Short term debt Â 135 516 385 379 Â 34% 36% Long term debt Â 852 3,263 3,376 3,031 Â -3% 8% (+) Lease Liabilities Â 38 147 158 154 Â -7% -4% Gross Debt Â 1,025 3,927 3,920 3,564 Â 0% 10% (-) Cash and cash equivalents / marketable securities Â 41 158 241 259 Â -35% -39% Net Debt Â 984 3,769 3,678 3,306 Â 2.5% 14.0% Leverage Ratio Â Â 4.13x 4.46x 4.89x Â -0.33x -0.76x Â Gross Debt at the close of 2Q24 increased10% YoY, or S/363 million, to S/3,927 million, due to: (i) a S/211 million increase related to previously reported refinancing activitiesin 2023, including the 2029 bond exchange premium, and; (ii) a S/152 million FX accounting effect. Compared to 4Q23, gross debt remainedflat, with a small increase of S/7 million.Â Debt Leverage decreased to 4.13x at theend of 2Q24 from 4.46x at year-end 2023 and 4.86x at the end of 2Q23, consistent with the Company's deleveraging plan, the medium-termtarget of which is 3.0x Net Debt-to-Adjusted LTM EBITDA.Â Consolidated DebtAmortization ProfileÂ (Figures in millions of Soles,unless expressed otherwise)Â Â Total Leases Y1 Y2 Y3 Y4 Y5 Y6+ Loans and Borrowings 3,780 0 516 601 416 553 721 972 Financial Leases 67 0 20 16 12 5 5 9 Operating Leases 81 81 0 0 0 0 0 0

Gross Debt 3,927 81 536 618 428 557 726 981 Â As of 2Q24. Excludes interest. Reflects figures post-refinancing.Y1 = July 2024 to June 2025, Y2 = July 2025 to June 2026, Y3 = July 2026 to June 2027, Y4 = July 2027 to June 2028, Y5 = July 2028 toJune 2029, and Y6+ = July 2029 to September 2035.Â 7Â Â Cashflow and CashConversion CycleÂ (Figures in millions of Solesand millions of US Dollars, unless expressed otherwise)Â Â Â Â YTD'24 (USD) YTD'24 YTD'23 Â Î" YTD'24 vs YTD'23 Net cash from operating activities Â Â 71 Â 271 Â 269 Â 1% Net cash used in investing activities Â Â (30) Â (116) Â (56) Â 107% Net cash used in from financing activities Â Â (61) Â (232) Â (146) Â 59% Cash and cash equivalents at the end of the period Â Â 41 Â 158 Â 259 Â -39% Â Â Â Â Â Â Â Â Â LTM Jun-23 LTM Mar-24 LTM Jun-24 Â Â Days Sales Outstanding Â 79 86 87 Â Â Days Inventory Outstanding Â 56 64 64 Â Â Days Payable Outstanding Â 104 119 124 Â Â Cash Conversion Cycle Â 31 31 27 Â Â *Measured on an average basis according to last twelve months results. Â Â Â Â Net cash from operating activities increased 1.0%YoY, or S/2 million, to S/271 million during the six months ended June 30, 2024. Operating cash flow was impacted by a S/38 million increasein tax payments in Mexico and Peru, due to higher profits and lower tax credits.Â Net cash used in investing activities increased107% YoY, or S/60 million, to S/116 million during the six months ended June 30, 2024, mainly due to non-recurring impacts related toinvestments in both periods. During the first six months of 2023, net cash used in extraordinary inorganic activity resulted in a positiveYoY impact of S/13 million. In addition, during the same period in 2023, Auna paid for the acquisition of AunaSeguros and made a partialpayment of the IMAT Oncomedica earnout obligation, although these payments were offset by a positive impact related to an IMAT Oncomedicaescrow account release and to the compensation of the advance payment made for the acquisition of the Monterrey healthcare business. Duringthe six months ended June, 2024, investing activities included the extraordinary inorganic impact of a S/47 million payment for the IMATOncomedica earnout obligation, with no offset during the period. The balance of investments during 2Q24 was mainly maintenance of CapExacross the three geographies and AunaSeguroâ€™s reserve requirements, which remained relatively flat versus the comparable periodin 2023.Â Net cash used in financing activities during thesix months ended 2024 was S/232 million, or an increase of S/86 million versus the comparable period in 2023, mainly due net inflows correspondingto refinancing activities in 2Q23, reducing financing cashflow consumption in 2Q23.Â 8Â Â About AUNAÂ Auna is a leading healthcare platform in LatinAmerican healthcare company with operations in Mexico, Peru and Colombia, prioritizing prevention and concentrating on high-complexitydiseases that contribute the most to healthcare expenditures. Our mission is to transform healthcare by providing access to a highly integratedhealthcare offering in the underpenetrated markets of Spanish-Speaking Americas. Founded in 1989, Auna has built one of Latin Americaâ€²slargest modern healthcare platforms that consists of a horizontally integrated network of healthcare facilities and a vertically integratedportfolio of oncological plans and selected general healthcare plans. As of June 30, 2024, Aunaâ€™s network included 31 healthcarenetwork facilities, consisting of hospitals, outpatient, prevention and wellness facilities with a total of 2,308 beds, and 1.3 millionhealthcare plans.Â For more information visit www.aunainvestors.comÂ Conference Call DetailsÂ When: 5:00 p.m. Eastern time, August 21st,2024Â Who: Mr. Suso Zamora, Executive Chairmanof the Board and President; Mrs. Gisele Remy, Chief Financial Officer and Executive Vice President;Â Ms. Ana Maria Mora, Head of Investor RelationsÂ Dial-in: +1 888 596 4144 (U.S. domestic),+1 646 968 2525 (International)Passcode: 3884034Â To access Aunaâ€²s financial results call viatelephone, callers need to press # to be connected to an operator.Â Webcast:click hereÂ Definitions and ConceptsÂ Figures in US dollars (US$ or USD) for 2Q24 arepresented for indicative purposes and were calculated using an FX rate of US$1= S/3.831. All comparisons in this announcement are year-over-year(â€œYoYâ€), unless otherwise noted; additionally, results are presented in an FX neutral basis (â€œFXNâ€) for consolidatedrevenues, consolidated cost of sales and services, consolidated selling and administrative expenses and consolidated adjusted EBITDA,as well as, in local currency for the Mexico and Colombia segments, to eliminate the effect of foreign exchange, or â€œFX,â€volatility between the comparison periods.Â Financial results are preliminary and subject toyear-end audit and adjustments for the year ended, December 31, 2024.Â Use of Non-IFRS Financial MeasuresÂ This release includes financial measures definedas â€œnon-IFRS financial measuresâ€ by the SEC, including: EBITDA, Segment EBITDA, Adjusted EBITDA, Adjusted Net Income, FX Neutral,EBITDA Margin, Adjusted EBITDA Margin, Adjusted Net Income Margin andÂ 9Â Â Leverage Ratio because we believe they assist investorsand analysts in comparing our operating performance across reporting periods on a consistent basis by excluding items that we do not believeare indicative of our core operating performance.Â In addition, management and our board of directorsuse these non-IFRS financial measures to assess our financial performance and believe they are helpful in highlighting trends in our coreoperating performance, while other measures can differ significantly depending on long-term strategic decisions regarding the growth ofour business. These are not measures of operating performance under IFRS and have limitations as analytical tools. You should not considersuch measures either in isolation or as substitutes for analyzing our results as reported under IFRS. Additionally, our calculations ofEBITDA, Segment EBITDA, Adjusted EBITDA, Adjusted Net Income, EBITDA Margin, Adjusted EBITDA Margin, Adjusted Net Income Margin, FX Neutraland Leverage Ratio may be different from the calculations used by other companies for similarly titled measures, including our competitors,and therefore may not be comparable to those of other companies.Â EBITDA: is calculated as profit (loss) beforetax for the period plus net finance cost and depreciation and amortization. EBITDA is a key metric used by management and our board ofdirectors to assess our financial performance.Â EBITDA Margin: is calculated as EBITDA dividedby total revenue from contracts with customers.Â Adjusted EBITDA: is calculated as profit(loss) before tax for the period plus net finance cost, depreciation and amortization, pre-operating expenses for projects under construction,business development (income) expenses for expansion into new markets, change in fair value of earn-out liabilities, stock-based considerationand personnel non-recurring compensation.Â Adjusted EBITDA Margin: is calculated asAdjusted EBITDA divided by total revenue from contracts with customers.Â Adjusted Last Twelve Month (â€œLTMâ€)EBITDA: is calculated by adding the last four quarters beginning with the corresponding period.Â Segment EBITDA: is calculated as segmentprofit before tax plus net finance cost and depreciation and amortization.Â Segment EBITDA Margin: is calculated assegment EBITDA divided by total segment revenue from contracts with customers.Â Segment Adjusted EBITDA: is calculated assegment profit (loss) before tax for the period plus net finance cost, depreciation and amortization, pre-operating expenses for projectsunder construction, business development (income) expenses for expansion into new markets, change in fair value of earn-out liabilities,stock-based consideration and personnel non-recurring compensation.Â 10Â Â Segment Adjusted EBITDA Margin: is calculatedas segment Adjusted EBITDA divided by total Segment revenue from contracts with customers.Â (Figures in millions of Solesand millions of US Dollars, unless expressed otherwise)Â Â Â Â Â Â Â Â Î" 2Q'24 vs Â Î" YTD'24 vs Â Â 2Q'24 (USD) 2Q'24 Â YTD'24 Â 1Q'24 2Q'23 Â YTD'23 Profit (Loss) before Tax Â 1 3 Â 19 Â -82% -93% Â -71% (+) Net Finance Cost Â 48 182 Â 350 Â 8% 90% Â 61% (+) Depreciation and Amortization Â 15 56 Â 112 Â -1% -1% Â -7% (=)

EBITDA Â 63 241 Â 482 Â 0% 24% Â 19% (+) Adjustments Â 1.9 7.1 Â 7.8 Â Â Â Â Â Pre-operating expenses Â 0.5 1.8 Â 2.2 Â Â Â Â Â Business development expenses Â 0.4 1.4 Â 1.4 Â Â Â Â Â Change in fair value of earn-out liabilities Â 0.0 0.0 Â 0.0 Â Â Â Â Â Stock-based consideration Â 0.1 0.3 Â 0.6 Â Â Â Â Â Personnel non-recurring compensation Â 0.9 3.6 Â 3.6 Â Â Â Â Â (=) Adjusted EBITDA Â 65 248 Â 489 Â 3% 31% Â 22% Adjusted EBITDA Margin Â Â 22.1% Â 20.7% Â -0.3 p.p. 2.0 p.p. Â -0.1 p.p. Â (a) Pre-operating expenses consist of legaland administrative expenses incurred in connection with medical facilities under construction, such as ClÃnica Chiclayo, costsrelating to the Torre Trecca PPP, and legal and administrative expenses incurred in connection with the acquisition of land banks forfuture facilities.Â (b) Business development expenses consistof expenses incurred in connection with projects to expand into new markets, including through greenfield projects and M&A activity.Â (c) Change in fair value of earn-out liabilitiesrelated to the acquisition of IMAT Oncomedica.Â (d) Stock-based consideration includesshare-based payments plans for non-executive members of the Board of DirectorsÂ (e) Personnel non-recurring compensationrelated to the implementation of an efficiency program across business units aimed at streamlining processes and capturing synergies onthe local and regional levels.Â At the segment level, 2Q24 adjustments includei) Pre-operating expenses of S/1.6 million in Healthcare Services Mexico and S/.2 million in Holdings and eliminations; ii) Business developmentexpenses of S/1.4 million in Healthcare Services Mexico; iii) Stock based consideration of S/.3 million in Holdings and eliminations,and iv) Personnel non-recurring compensation of S/2 million in Healthcare Services Mexico and S/1.6 million in Healthcare Services Peru.Â In 2Q23 adjustments include i) Pre-operating expensesof S/.3 million in Holdings and eliminations; and ii) Change in fair value of earn out liabilities of S/-4.1 million in Healthcare ServicesColombia.Â Consolidated Peru Adjusted EBITDA: is calculatedby adding Healthcare Services Peru segment Adjusted EBITDA plus Oncosalud Peru segment Adjusted EBITDA.Â Consolidated Peru Adjusted EBITDA margin:is calculated as Healthcare Services Peru segment Adjusted EBITDA plus Oncosalud Peru segment Adjusted EBITDA, divided by total revenuesfrom Healthcare Services Peru Segment plus total revenues from Oncosalud Peru segment.Â Â 11Â Â Adjusted Net Income: is calculated as profit(loss) for the period plus adjustments as described below.Â (Figures in millions of Solesand millions of US Dollars, unless expressed otherwise)Â Â Â 2Q'24 (USD) 2Q'24 2Q'23 YTD'24 YTD'23 Net Income (Loss) Â 2 8 23 (0) 23 (+) Pre-operating expenses Â 0.5 1.8 0.3 2.2 0.3 (+) Business development expenses Â 0.4 1.4 0.0 1.4 0.6 (+) Change in fair value of earn-out liabilities Â 0.0 0.0 -4.1 0.0 -4.1 (+) Stock-based consideration Â 0.1 0.3 0.0 0.6 0.0 (+) Personnel non-recurring compensation Â 0.9 3.6 0.0 3.6 0.0 (+) Non-cash and extraordinary financial costs Â 0.0 0.0 18.6 29.6 18.6 (+) Allocated tax effects Â (0.6) (2.1) (1.1) (2.3) (1.3) (=) Adjusted Net Income Â 3 13 36 35 37 Â (a) Pre-operating expenses consist of legal andadministrative expenses incurred in connection with medical facilities under construction, such as ClÃnica Chiclayo, costs relatingto the Torre Trecca PPP, and legal and administrative expenses incurred in connection with the acquisition of land banks for future facilities.(b) Business development expenses consist of expensesincurred in connection with projects to expand into new markets, including through greenfield projects and M&A activity.(c) Change in fair value of earn-out liabilitiesrelated to the acquisition of IMAT Oncomedica.(d) Stock-based consideration includes share-basedpayments plans for non-executive members of the Board of Directors.(e) Personnel non-recurring compensation relatedto the implementation of an efficiency program across business units aimed at streamlining processes and capturing synergies on the localand regional levels.(f) Non-cash and extraordinary financial costsinclude; 1) one-time extraordinary costs of refinancing activities; ii) non-cash derivative costs related to mark to market of legacyderivatives related to extinguished financings; and iii) non-cash effects related to early extinguishment of financings.(g) Allocated tax effects neutralize the tax shieldthat the items considered as adjustment have generated in the taxable profit.Â Basic and Diluted Earnings per Share: Basicand Diluted Earnings per Share is calculated by dividing the profit attributable to owners of the Company by the weighted average numberof ordinary shares outstanding during the period, which excludes treasury shares.Â Adjusted Basic and Diluted Earnings per Share:Adjusted Basic and Diluted Earnings per Share is calculated by dividing profit attributable to owners of Adjusted Net Income of theCompany by the weighted average number of ordinary shares outstanding during the period, which excludes treasury shares.Â Â 2Q'24 (USD) 2Q'24 2Q'23 YTD'24 YTD'23 Net Income (Loss) 2 8 23 (0) 23 Income (Loss) attributable to Owner of the company 1 4 2 (10) (2) Weighted average number of ordinary shares at June 30 Â 74.0 43.9 60.6 43.9 Basic and diluted earnings per share 0.01 0.05 0.04 (0.16) (0.05) Adjusted Net Income (Loss) 3 13 36 35 37 Income (Loss) attributable to owners of Adjusted Net Income 2 9 15 25 12 Weighted average number of ordinary shares at June 30 Â 74.0 43.9 60.6 43.9 Adjusted Basic and Diluted Earnings per Share 0.03 0.12 0.35 0.42 0.27 Â 12Â Â Leverage Ratio: We calculate Leverage Ratioas (i) current and non-current loans and borrowings plus current and non-current lease liabilities minus (ii) cash and cash equivalents,divided by (iii) Last twelve months Adjusted EBITDA.Â Â Jun-23 Dec-23 Jun-24 Â Current and non-current loans & borrowings 3,410 3,762 3,780 Current and non-current lease liabilities 154 158 147 Cash and cash equivalents 259 241 158 Net Debt 3,306 3,678 3,769 Adjusted LTM EBITDA 676 825 913 Leverage Ratio 4.89x 4.46x 4.13x Â Net Debt: We calculate Net Debt as GrossDebt minus Cash and cash equivalents.Â Â Â Jun-23 Dec-23 Jun-24 Â Â (+) Loans and borrowings Â 3,410 3,762 3,780 Short term debt Â 379 385 516 Long term debt Â 3,031 3,376 3,263 (+) Lease Liabilities Â 154 158 147 Gross Debt Â 3,564 3,920 3,927 (-) Cash and cash equivalents Â 259 241 158 Net Debt Â 3,306 3,678 3,769 Â FX Neutral: FX Neutral (â€œFXNâ€)measures are prepared and presented to eliminate the effect of foreign exchange, or â€œFX,â€ volatility between the comparisonperiods, allowing management and investors to evaluate financial performance despite variations in foreign currency exchange rates, whichmay not be indicative of core operating results and business outlook.Â FX Neutral measures arepresented because management believes that these non-IFRS financial measures can provide useful information to investors, securities analystsand the public in their review of operating and financial performance, although they are not calculated in accordance with IFRS or anyother generally accepted accounting principles and should not be considered as a measure of performance in isolation.Â The FX Neutral measureswere calculated to present what such measures in preceding periods would have been had exchange rates remained stable from these precedingperiods until the date of the Company's most recent financial information.Â The FX Neutral measuresfor the three months ended June 30, 2023 were calculated by multiplying the as reported amounts of Revenue, Adjusted EBITDA and the keybusiness metrics for such period by the average Mexican pesos / Peruvian soles exchange rate for the three months ended June 30, 2023(MXN 4.7747 to PEN 1.00) and the average Colombian pesos / Peruvian soles exchange rate for the three months ended June 30,Â 13Â Â 2023 (COP 1,189.3388 toPEN 1.00); then using such results to re-translate the corresponding amounts back to Peruvian soles by dividing them by the average Mexicanpesos / Peruvian soles and Colombian pesos / Peruvian soles exchange rate for the three months ended June 30, 2024 (MXN 4.5975 to PEN1.00 / COP 1,048.4972 to PEN 1.00), so as to present what certain of statement of profit and loss amounts and key business metrics wouldhave been had exchange rates remained stable from this past period until the three months ended June 30, 2024.Â Safe Harbor StatementÂ This press release contains forward-looking statements.Forward-looking statements convey our current expectations or forecasts of future events. These statements involve known and unknown risks,uncertainties and other factors which may cause our actual results, performance or achievements to differ materially from the forward-lookingstatements that we make. Forward-looking statements typically are identified by words or phrases such as â€œmay,â€ â€œwill,â€â€œexpect,â€ â€œanticipate,â€ â€œaim,â€ â€estimate,â€ â€œintend,â€ â€œproject,â€â€œplan,â€ â€œbelieve,â€ â€œpotential,â€ â€œcontinue,â€ â€œis/are likely to, â€or other similarexpressions. Forward-looking statements that appear in a number of places in this press release include, but are not limited to, statementsregarding the intent, belief or current expectations, regarding various matters, including, our expected 2024 Adjusted EBITDA growth,the expected impact on revenues and profitability of certain initiatives we are pursuing in Mexico and our target leverage level. Anyor all of our forward-looking statements in this press release may turn out to be inaccurate. Our actual results could differ materiallyfrom those contained in forward-looking statements due to a number of factors.Â The forward-looking statements in this press releaserepresent our expectations and forecasts as of the date of this press release. Except as required by law, we undertake no obligation toupdate or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after thedate of this press release. For a discussion of the risks facing the Company which could affect whether these forward-looking statementsare realized, see our Form F-1 filing with the U.S. Securities and Exchange Commission.Â 2024 Financial Guidance DisclaimerÂ Aunaâ€²s guidance is based on managementâ€™scurrent performance outlook and expected macroeconomic and regulatory conditions in the three countries where the Company operates. Anychanges in these conditions could have an impact on the guidance provided.Â The 2024 financial guidance reflects managementâ€™scurrent assumptions regarding numerous evolving factors that are difficult to accurately predict, including those discussed in the RiskFactors set forth in the Companyâ€™s Form F-1 filed with the United States Securities and Exchange Commission (the â€œSECâ€).Reconciliations of forward-looking non-IFRS measures, specifically the 2024 EBITDA guidance, to the relevant forward-looking IFRS measuresare not being provided, as the Company does not currently have sufficient data to accurately estimate the variables and individual adjustmentsfor such guidance and reconciliations. Due to this uncertainty, the Company cannot reconcile projected EBITDA to projected net incomewithout unreasonable effort.Â 14Â Â The 2024 financial guidance constitutes forward-lookingstatements. For more information, see the â€œForward-Looking Statementsâ€ section in this release.Â IR Contact Â Email: contact@aunainvestors.comÂ - Financial Tables Follow â€“Â 15Â Â Balance SheetÂ (Figures in millions of Solesand millions of US Dollars, unless expressed otherwise)Â Â Jun-24 (USD) Jun-24 Dec-23 Â Î” Jun-24 vs Dec-23 Assets Â Â Â Â Â Current assets Â Â Â Â Â Cash and cash equivalents Â 41 Â 158 Â 241 Â Â (83) Trade accounts receivable Â 255 Â 976 Â 861 Â Â 115 Other assets Â 60 Â 231 Â 223 Â Â 9 Inventories Â 32 Â 123 Â 131 Â Â (7) Derivative financial instruments Â -Â Â -Â Â 1 Â Â (1) Other investments Â 27 Â 102 Â 93 Â Â 9 Total current assets Â 415 Â 1,591 Â 1,549 Â Â 42 Non-current assets Â Â Â Â Â Trade accounts receivable Â 0 Â 1 Â 0 Â Â 0 Other assets Â 6 Â 23 Â 22 Â Â 1 Investments in associates and joint venture Â 6 Â 22 Â 21 Â Â 2 Property furniture and equipment Â 645 Â 2,470 Â 2,573 Â Â (103) Intangible assets Â 779 Â 2,984 Â 3,129 Â Â (145) Right-of-use assets Â 33 Â 128 Â 139 Â Â (12) Investment properties Â 2 Â 7 Â 7 Â Â (0) Derivative financial instruments Â 17 Â 66 Â 81 Â Â (15) Deferred tax assets Â 53 Â 201 Â 167 Â Â 34 Other investments Â 0 Â 0 Â 0 Â Â (0) Total non-current assets Â 1,541 Â 5,902 Â 6,140 Â Â (239) Total assets Â 1,956 Â 7,492 Â 7,690 Â Â (197) Liabilities Â Â Â Â Â Current liabilities Â Â Â Â Â Loans and borrowings Â 135 Â 516 Â 385 Â Â 131 Lease liabilities Â 8 Â 31 Â 32 Â Â (1) Trade accounts payable Â 220 Â 843 Â 749 Â Â 94 Other accounts payable Â 127 Â 485 Â 464 Â Â 22 Provisions Â 4 Â 17 Â 19 Â Â (2) Insurance contract liabilities Â 12 Â 45 Â 40 Â Â 5 Deferred income Â 0 Â 0 Â 0 Â Â (0) Total current liabilities Â 506 Â 1,938 Â 1,689 Â Â 248 Non-current liabilities Â Â Â Â Â Loans and borrowings Â 852 Â 3,263 Â 3,376 Â Â (113) Lease liabilities Â 30 Â 116 Â 126 Â Â (10) Trade accounts payable Â 1 Â 4 Â 4 Â Â (0) Other accounts payable Â 23 Â 88 Â 221 Â Â (133) Derivative financial instruments Â 11 Â 42 Â -Â Â Â 42 Deferred tax liabilities Â 106 Â 407 Â 496 Â Â (89) Deferred income Â 0 Â 0 Â 0 Â Â (0) Total non-current liabilities Â 1,023 Â 3,920 Â 4,224 Â Â (304) Total liabilities Â 1,529 Â 5,858 Â 5,913 Â Â (55) Total Equity Â 427 Â 1,635 Â 1,777 Â Â (142) Total liabilities and equity Â 1,956 Â 7,492 Â 7,690 Â Â (197) Â 16Â Â Income Statement Â (Figures in millions of Solesand millions of US Dollars, unless expressed otherwise)Â Â 2Q'24 (USD) 2Q'24 2Q'23 YTD'24 YTD'23 Â Î” 2Q'24 vs Î” YTD'24 vs Â Â 2Q'23 YTD'23 Revenue Â Â Â Â Â Â Â Â Healthcare Services Mexico Â Â Â Â Â Â 79 Â Â Â Â Â 302 Â Â Â Â Â 281 Â Â Â Â Â Â Â 611 Â Â Â Â Â Â Â 552 Â 7% 11% Healthcare Services Colombia Â Â Â Â Â Â 99 Â Â Â Â Â 378 Â Â Â Â Â 282 Â Â Â Â Â Â Â 727 Â Â Â Â Â Â Â 534 Â 34% 36% Healthcare Services Peru & Oncosalud Peru Â Â Â Â 115 Â Â Â Â Â 441 Â Â Â Â Â 383 Â Â Â Â Â Â Â 859 Â Â Â Â Â Â Â 754 Â 15% 14% - Healthcare Services Peru Â Â Â Â Â Â 67 Â Â Â Â Â 255 Â Â Â Â Â 217 Â Â Â Â Â Â Â 496 Â Â Â Â Â Â Â 429 Â 18% 16% - Oncosalud Peru Â Â Â Â Â Â 70 Â Â Â Â Â 269 Â Â Â Â Â 230 Â Â Â Â Â Â Â 522 Â Â Â Â Â Â Â 451 Â 17% 16% - Holding and eliminations Â Â Â Â (22) Â Â Â Â Â (83) Â Â Â Â Â (64) Â Â Â Â Â (159) Â Â Â Â Â (126) Â 30% 26% Total Revenue 292 1,120 946 2,197 1,840 Â 18% 19% Cost of sales and services (181) (693) (586) (1,355) (1,152) Â 18% 18% Gross profit 112 427 360 842 688 Â 19% 22% Gross margin Â 38.1% 38.0% 38.3% 37.4% Â 0.1 p.p. 0.9 p.p. Selling expenses Â Â Â Â (12) Â Â Â Â Â (48) Â Â Â Â Â (51) Â Â Â Â Â (101) Â Â Â Â Â Â Â Â Â (97) Â -7% 4% Administrative expenses Â Â Â Â (53) Â Â Â (202) Â Â Â (191) Â Â Â Â Â (392) Â Â Â Â Â (335) Â 5% 17% (Loss) reversal for impairment of trade receivables Â Â Â Â Â Â (1) Â Â Â Â Â Â Â Â Â (3) Â Â Â Â Â Â Â Â Â (2) Â Â Â Â Â Â Â Â Â Â Â (3) Â Â Â Â Â Â Â Â Â Â Â (3) Â 88% 2% Other income and expenses, net Â Â Â Â Â Â Â Â Â 2 Â Â Â Â Â Â Â Â Â Â Â Â 8 Â Â Â Â Â Â Â Â 20 Â Â Â Â Â Â Â Â Â Â Â 19 Â Â Â Â Â Â Â Â Â Â Â 28 Â -63% -32% Operating profit 48 Â Â Â Â Â 183 Â Â Â Â Â 136 Â Â Â Â Â Â Â 365 Â Â Â Â Â Â Â 281 Â 34% 30% Finance income Â Â Â Â Â Â Â Â 2 Â Â Â Â Â Â Â Â Â Â Â Â 7 Â Â Â Â Â Â Â Â 33 Â Â Â Â Â Â Â Â Â Â Â 15 Â Â Â Â Â Â Â Â Â Â Â 51 Â -80% -70% Finance costs Â Â Â Â (49) Â Â Â (189) Â Â Â (129) Â Â Â Â Â (365) Â Â Â Â Â (268) Â 46% 36% Net finance cost Â Â Â Â (48) Â Â Â (182) Â Â Â Â Â (96) Â Â Â Â Â (350) Â Â Â Â Â (217) Â 90% 61% Share of profit of equity accounted investees Â Â Â Â Â Â Â Â 1 2 2 5 3 Â 36% 60% Profit (loss) before tax 1 Â Â Â Â Â Â Â Â Â Â Â 3 Â Â Â Â Â Â Â Â 42 Â Â Â Â Â Â Â Â Â Â Â Â 19 Â Â Â Â Â Â Â Â Â Â Â Â 66 Â -93% -71% Income tax expense (benefit) Â Â Â Â Â Â Â Â Â 1 Â Â Â Â Â Â Â Â Â Â Â Â 5 Â Â Â Â Â Â (19) Â Â Â Â Â Â Â Â Â (19) Â Â Â Â Â Â Â Â Â (43) Â -126% -55% Net Income (Loss) Â Â Â Â Â Â Â Â Â 2 Â Â Â Â Â Â Â Â Â Â Â Â 8 Â Â Â Â Â Â Â Â 23 Â Â Â Â Â Â Â Â Â Â Â Â (0) Â Â Â Â Â Â Â Â Â Â Â Â 23 Â -65% -102% EBITDA Â Â Â Â Â Â Â Â Healthcare Services Mexico 25 Â Â Â Â Â Â Â Â 95 Â Â Â Â Â Â Â Â 96 Â Â Â Â Â Â Â Â 199 Â Â Â Â Â Â Â Â 209 Â -1% -5% Healthcare Services Colombia 15 Â Â Â Â Â Â Â Â 58 Â Â Â Â Â Â Â Â 50 Â Â Â Â Â Â Â Â 108 Â Â Â Â Â Â Â Â Â Â Â Â 86 Â 15% 25% Healthcare Services Peru & Oncosalud Peru 24 Â Â Â Â Â Â Â Â 92 Â Â Â Â Â Â Â Â 48 Â Â Â Â Â Â Â Â 177 Â Â Â Â Â Â Â Â 109 Â 92% 63% - Healthcare Services Peru 10 Â Â Â Â Â Â Â Â 38 Â Â Â Â Â Â Â Â 10 Â Â Â Â Â Â Â Â Â Â Â Â 75 Â Â Â Â Â Â Â Â Â Â Â Â 31 Â 302% 141% - Oncosalud Peru 14

Â Â Â Â Â Â Â 54 Â Â Â Â Â Â Â Â 38 Â Â Â Â Â Â Â Â 102 Â Â Â Â Â Â Â Â Â Â Â 77 Â 40% 32% - Holding and eliminations Â Â Â Â Â Â Â (1) Â Â Â Â Â Â Â Â Â Â (4) Â Â Â Â Â Â Â Â Â Â (1) Â Â Â Â Â Â Â Â Â Â Â Â (2) Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â 0 Â Â Â Total EBITDA Â Â Â Â Â Â 63 Â Â Â Â Â Â 241 Â Â Â Â Â Â 194 Â Â Â Â Â Â Â Â 482 Â Â Â Â Â Â Â Â 404 Â 24% 19% Adjusted EBITDA Â Â Â Â Â Â Â Â Healthcare Services Mexico 26 Â Â Â Â Â Â 100 Â Â Â Â Â Â Â Â 96 Â Â Â Â Â Â Â Â 204 Â Â Â Â Â Â Â Â 209 Â 4% -3% Healthcare Services Colombia 15 Â Â Â Â Â Â Â Â 58 Â Â Â Â Â Â Â Â 46 Â Â Â Â Â Â Â Â 108 Â Â Â Â Â Â Â Â Â Â Â Â 82 Â 25% 31% Healthcare Services Peru & Oncosalud Peru 24 Â Â Â Â Â Â Â Â 93 Â Â Â Â Â Â Â Â 48 Â Â Â Â Â Â Â Â 179 Â Â Â Â Â Â Â Â 109 Â 96% 65% - Healthcare Services Peru 10 Â Â Â Â Â Â Â Â 40 Â Â Â Â Â Â Â Â 10 Â Â Â Â Â Â Â Â Â Â Â 77 Â Â Â Â Â Â Â Â Â Â Â 31 Â 318% 146% - Oncosalud Peru 14 Â Â Â Â Â Â Â Â 54 Â Â Â Â Â Â Â Â 38 Â Â Â Â Â Â Â Â 102 Â Â Â Â Â Â Â Â Â Â Â 77 Â 40% 32% - Holding and eliminations Â Â Â Â Â Â Â (1) Â Â Â Â Â Â Â Â Â Â (3) Â Â Â Â Â Â Â Â Â Â (1) Â Â Â Â Â Â Â Â Â Â Â Â (1) 1 Â Â Â Total Adjusted EBITDA Â Â Â Â Â Â 65 Â Â Â Â Â Â 248 Â Â Â Â Â Â 190 Â Â Â Â Â Â Â Â 489 Â Â Â Â Â Â Â Â 401 Â 31% 22% Adjusted EBITDA Margin Â Â Â Â Â Â Â Â Healthcare Services Mexico Â 33.1% 34.3% 33.4% 37.9% Â -1.2 p.p. -4.5 p.p. Healthcare Services Colombia Â 15.3% 16.5% 14.8% 15.4% Â -1.1 p.p. -0.5 p.p. Healthcare Services Peru & Oncosalud Peru Â 21.2% 12.5% 20.8% 14.4% Â 8.7 p.p. 6.4 p.p. - Healthcare Services Peru Â 15.6% 4.4% 15.5% 7.3% Â 11.2 p.p. 8.2 p.p. - Oncosalud Peru Â 19.9% 16.6% 19.5% 17.2% Â 3.3 p.p. 2.4 p.p. Adjusted EBITDA Margin Â 22.1% 20.1% 22.3% 21.8% Â 2.0 p.p. 0.5 p.p. Â 17Â Â Statement of Cash FlowsÂ (Figures in millions of Solesand millions of US Dollars, unless expressed otherwise)Â Â Jun-24 (USD) YTD'24 YTD'23 Â Î” YTD'24 vs YTD'23 Cash flows from operating activities Â Â Â Â Â (Loss) profit for the period Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â (0) Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â (0) Â Â Â Â Â Â Â Â Â Â Â Â Â Â 23 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â (23) Adjustments for: Â Â Â Â Â Depreciation Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â 16 Â Â Â Â Â Â Â Â Â Â Â Â Â Â 60 Â Â Â Â Â Â Â Â Â Â Â Â Â Â 70 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â (10) Depreciation of right-of-use assets Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â 4 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â 14 Â Â Â Â Â Â Â Â Â Â Â Â Â Â 12 Â 1 Amortization Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â 10 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â 39 Â Â Â Â Â Â Â Â Â Â Â Â Â Â 38 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â 1 (Gain) loss for Impairment of inventories Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â (1) Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â (2) Â Â Â Â Â Â Â Â Â Â Â Â Â (0) Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â (2) Equity-settled share-based payment transactions Â 0 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â 1 Â Â Â Â Â Â Â Â Â Â Â Â Â Â -Â Â Â Â Â 1 Gain (loss) on disposal of property furniture and equipment Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â 0 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â 1 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â 1 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â (0) Loss on disposal of right-of-use assets net of leases Â 0 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â 0 Â Â Â Â Â Â Â Â Â Â Â Â Â Â (0) Â 0 Loss on disposal of intangibles Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â 0 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â 1 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â 0 Â Â 1 Other income for reversal of contingent consideration Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â -Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â -Â Â Â Â Â Â Â Â Â Â Â Â Â Â (4) Â Â 4 (Gain) loss for impairment of trade receivables Â 1 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â 3 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â 3 Â 0 Share of profit of equity-accounted investees Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â (1) Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â (5) Â Â Â Â Â Â Â Â Â Â Â Â Â Â (3) Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â (2) Technical provisions and other provisions Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â 0 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â 0 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â 0 Â 0 Finance income Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â (4) Â Â Â Â Â Â Â Â Â Â Â Â Â Â (15) Â Â Â Â Â Â Â Â Â Â Â Â (51) Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â 36 Finance costs Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â 95 Â Â Â Â Â Â Â Â Â Â Â Â Â Â 365 Â Â Â Â Â Â Â Â Â Â Â Â 268 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â 97 Income tax expense Â 5 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â 19 Â Â Â Â Â Â Â Â Â Â Â Â Â Â 43 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â (24) Net changes in assets and liabilities Â Â Â Â Â Trade accounts receivable and other assets Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â (55) Â Â Â Â Â Â Â Â Â Â Â Â (212) Â Â Â Â Â Â Â Â Â Â Â (130) Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â (81) Inventories Â 2 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â 7 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â 1 Â 6 Trade accounts payable and other accounts payable Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â 24 Â Â Â Â Â Â Â Â Â Â Â Â Â Â 92 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â 45 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â 47 Provisions Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â (1) Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â (2) Â Â Â Â Â Â Â Â Â Â Â Â Â Â (1) Â (1) Insurance contract liabilities Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â 2 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â 6 Â Â Â Â Â Â Â Â Â Â Â Â Â Â 20 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â (14) Cash generated from operating activities Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â 97 Â Â Â Â Â Â Â Â Â Â Â Â Â Â 371 Â Â Â Â Â Â Â Â Â Â Â Â 335 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â 36 Income tax paid Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â (29) Â Â Â Â Â Â Â Â Â Â Â Â (111) Â Â Â Â Â Â Â Â Â Â Â Â (73) Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â (38) Interest received Â 3 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â 12 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â 7 Â Â 5 Net cash from operating activities Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â 71 Â Â Â Â Â Â Â Â Â Â Â Â Â Â 271 Â Â Â Â Â Â Â Â Â Â Â Â 269 Â 3 Â 18Â Â Â Jun-24 (USD) YTD'24 YTD'23 Â Î” YTD'24 vs YTD'23 Cash flows from investing activities Â Â Â Â Â Acquisition of subsidiary net of cash acquired Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â -Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â -Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â (60) Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â 60 Purchase of properties furniture and equipment Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â (9) Â Â Â Â Â Â Â Â Â Â Â Â Â Â (35) Â Â Â Â Â Â Â Â Â Â Â Â (40) Â 5 Purchase of intangibles Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â (6) Â Â Â Â Â Â Â Â Â Â Â Â Â Â (22) Â Â Â Â Â Â Â Â Â Â Â Â (15) Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â (7) Dividends from equity-accounted investees Â 0 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â 1 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â -Â Â Â Â 1 Other assets (Trust funds) Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â -Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â -Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â 95 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â (95) Purchase of other investments net of sales Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â (3) Â Â Â Â Â Â Â Â Â Â Â Â Â Â (13) Â Â Â Â Â Â Â Â Â Â Â Â (15) Â 2 Proceeds from sale of property furniture and equipment Â 0 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â 0 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â 1 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â (0) Payment for contingent consideration Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â (12) Â Â Â Â Â Â Â Â Â Â Â Â Â (47) Â Â Â Â Â Â Â Â Â Â Â Â (33) Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â (14) Proceeds from advance payment for purchase of shares Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â -Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â -Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â 12 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â (12) Net cash used in investing activities Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â (30) Â Â Â Â Â Â Â Â Â Â Â Â (116) Â Â Â Â Â Â Â Â Â Â Â Â (56) Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â (60) Financing activities Â Â Â Â Â Proceeds from issuance of common stock in initial public offering, net of issuance costs Â Â Â Â Â Â Â Â Â Â Â Â Â Â 331 Â Â Â Â Â Â Â Â Â Â 1,268 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â -Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â 1,268 Payments of initial public offering costs Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â (4) Â Â Â Â Â Â Â Â Â Â Â Â Â Â (16) Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â -Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â (16) Proceeds from loans and borrowings Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â 124

Â Â Â Â Â Â Â Â Â Â Â 475 Â Â Â Â Â Â 2,261 Â Â Â Â Â Â Â Â Â Â (1,786) Payment for loans and borrowings Â Â Â Â Â Â Â Â Â Â Â Â (114) Â Â Â Â Â Â Â Â Â Â (437) Â Â Â Â Â Â (2,112) Â Â Â Â Â Â Â Â Â Â Â Â 1,674 Payment for lease liabilities Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â (6) Â Â Â Â Â Â Â Â Â Â Â Â (23) Â Â Â Â Â Â Â Â Â Â (20) Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â (2) Payment for costs of Extinguishment of debt Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â (4) Â Â Â Â Â Â Â Â Â Â Â Â (17) Â Â Â Â Â Â Â Â Â Â Â Â -Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â (17) Payment for derivatives premiums Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â (9) Â Â Â Â Â Â Â Â Â Â Â Â (35) Â Â Â Â Â Â Â Â Â Â (15) Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â (20) Interest paid Â Â Â Â Â Â Â Â Â Â Â Â Â Â (60) Â Â Â Â Â Â Â Â Â Â (229) Â Â Â Â Â Â Â Â Â (253) Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â 24 Dividends paid Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â -Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â -Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â (7) Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â 7 Acquisition of non-controlling interest Â Â Â Â Â Â Â Â Â Â Â Â (318) Â Â Â Â Â Â Â Â (1,218) Â Â Â Â Â Â Â Â Â Â Â Â Â -Â Â Â Â Â Â Â Â Â Â Â Â Â Â (1,218) Net cash used in financing activities Â Â Â Â Â Â Â Â Â Â Â Â Â Â (61) Â Â Â Â Â Â Â Â Â Â (232) Â Â Â Â Â Â Â Â (146) Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â (86) Net increase in cash and cash equivalents Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â (20) Â Â Â Â Â Â Â Â Â Â Â Â Â Â (77) Â Â Â Â Â Â Â Â Â Â Â Â Â Â 67 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â (143) Cash and cash equivalents at January 1 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â 63 Â Â Â Â Â Â Â Â Â Â Â Â Â 241 Â Â Â Â Â Â Â Â Â Â 209 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â 32 Â Exchange difference on cash and cash equivalents for the period Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â (2) Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â (7) Â Â Â Â Â Â Â Â Â Â Â (17) Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â 10 Â Cash and cash equivalents at the end of the period Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â 41 Â Â Â Â Â Â Â Â Â Â Â Â Â 158 Â Â Â Â Â Â Â Â Â Â Â 259 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â (101) Â 19Â Â Historical Financial MetricsÂ (Figures in millions of Solesand millions of US Dollars, unless expressed otherwise)Â Â 2Q'22 3Q'22 4Q'22 1Q'23 2Q'23 3Q'23 4Q'23 1Q'24 2Q'24 Â Â Â Â Â Â Â Â Â Revenue Â Â Â Â Â Â Â Â Â Oncosalud Peru 199 204 215 221 230 237 244 253 269 Healthcare Services Peru 179 193 190 212 217 230 225 241 255 Healthcare Services Colombia 239 254 237 252 282 324 335 349 378 Healthcare Services Mexico 0 0 216 271 281 294 284 308 302 Holding and eliminations (52) (54) (54) (62) (64) (69) (67) (76) (83) Total revenue from contracts with customers 566 597 804 894 946 1,015 1,021 1,076 1,120 Cost of sales and services (358) (380) (525) (566) (586) (643) (645) (662) (693) Gross profit 208 217 279 328 360 372 376 414 427 Selling expenses (45) (44) (39) (46) (51) (55) (42) (53) (48) Administrative expenses (115) (114) (153) (144) (191) (177) (193) (191) (202) Impairment losses on trade receivables 1 1 (2) (1) (2) (1) (2) 0 (3) Other expenses 0 0 (1) 0 0 0 (21) 0 0 Other income 9 5 6 8 20 10 13 11 8 Operating profit 59 66 90 145 136 149 130 182 183 Finance income 1 1 (2) 18 33 3 39 9 7 Finance costs (73) (83) (124) (139) (129) (175) (340) (177) (189) Net finance cost (72) (82) (126) (122) (96) (172) (302) (168) (182) Share of profit of equity-accounted investees 1 1 1 1 2 2 1 2 2 Profit (loss) before tax (12) (16) (36) 24 42 (20) (170) 16 3 Income tax (expense) benefit (5) 17 (37) (24) (19) 3 (50) (25) 5 Net Income (17) 1 (73) 0 23 (18) (219) (8) 8 EBITDA 86 94 155 210 194 210 188 241 241 EBITDA Adjustments Â Â Â Â Â Â Â Â Â Net Income (17) 1 (73) 0 23 (18) (219) (8) 8 Income tax expense 5 (17) 37 24 19 (3) 50 25 (5) Net finance cost 72 82 126 122 96 172 302 168 182 Depreciation and amortization 25 27 64 65 56 59 56 56 56 Pre-operating expenses 9 4 21 0 0 1 0 0 2 Business development expenses 1 1 1 1 0 0 0 0 1 Change in fair value of earn-out liabilities 0 0 0 0 (4) 0 21 0 0 Stock-based consideration 0 0 0 0 0 0 4 0 0 Personnel non-recurring compensation 0 0 0 0 0 0 0 0 4 Adjusted EBITDA 95 98 177 211 190 211 213 241 248 Â 20Â Â Key Operating MetricsÂ Â YTD'24 YTD'23 % Change Oncosalud Peru Â Â Â Plan memberships (1) (2) Â Â Â 1,263,495 Â Â Â 1,204,040 4.9% Average monthly revenue per plan member (3) Â S/Â Â Â Â Â 59.64 Â S/Â Â Â Â Â 57.97 2.9% Preventive check-ups (4) 51,909 67,577 -23.2% Patients treated (5) 44,581 43,218 3.2% Medical loss ratio (6) 58.6% 51.2% 7.4 p.p Â Â Â Â Healthcare Services Â Â Â Total bed capacity (1) Â Â Â Â Â Â Â Â Â Â 2,199 Â Â Â Â Â Â Â Â Â Â 2,192 0.3% Surgeries (7) Â Â Â Â Â Â Â Â Â 44,119 Â Â Â Â Â Â Â Â Â 43,908 0.5% Emergency treatments (8) Â Â Â Â Â Â Â 175,188 Â Â Â Â Â Â Â 176,719 -0.9% Occupancy (operating capacity) (9) 79.9% 77.7% 2.1 p.p Occupancy (total capacity) (10) 66.5% 62.7% 3.7 p.p Â 1)As of period end and as reported to the National Superintendence of Health Susalud. Includes Oncologyplans and Health plans.2)Includes active plan members and inactive members. Inactive members are defined as those plan membersthat have not paid monthly fees due for up to three months. As of June 30, 2024, we had 1,155,041 active members and 108,454 inactivemembers.3)Total revenue for the period corresponding to insurance revenue in the OncoSalud Peru segment dividedby the average number of plan members during the period, divided by the number of months in the period.4)Preventive check-ups consider Oncology check-ups at the Centro de Bienestar Ambulatorio â€" CBA (wellnesscenter) in Lima, Peru. The number of Healthcare checkups is negligent.5)Number of individual plan members receiving treatment for cancer during the period, which may includemultiple instances of treatment per plan member.6)MLR is calculated as (i) claims for medical treatment generated by our prepaid oncology and general healthcareplans plus (ii) technical reserves relating to plan members treated pursuant to such plans, whether at our facilities or third-party facilities,divided by revenue generated by our prepaid oncology and general healthcare plans.7)Number of surgeries includes surgeries outpatient surgeries and cesarean sections8)Emergency care includes the number of visits in the emergency room and may include several visits perpatient.9)Occupancy (operating capacity) is calculated as (i) (x) total number of days in which any of our bedshad a hospitalized patient during the period divided by (y) total number of operating beds, times (ii) total number of days during theperiod.10)Occupancy (total capacity) is calculated as (i) (x) total number of days in which any of our beds hada hospitalized patient during the period divided by (y) total number of beds, times (ii) total number of days during the period.Â 21Â Exhibit 99.2Â Â Â Â Auna S.A. and SubsidiariesCondensed Consolidated Interim Financial StatementsJune 30, 2024Â Â Â Auna S.A. and Subsidiaries Â Condensed Consolidated Interim Financial StatementsÂ Â June 30, 2024Â Â Â Contents Page Condensed Consolidated Interim Statement of Financial Position 1 Condensed Consolidated Interim Statement of Income and Other Â Comprehensive Income (Loss) 2 Condensed Consolidated Interim Statement of Changes in Equity 3 Condensed Consolidated Interim Statement of Cash Flows 4 Operating Segments 5 - 10 Â Â Â Auna S.A. and Subsidiaries Condensed Consolidated Interim Statement of Financial Position As of June 30, 2024 and December 31, 2023 Â In thousands of solesÂ June 30, 2024Â December 31, 2023Â In thousands of solesÂ June 30, 2024Â December 31, 2023 AssetsÂ Â Â Â Â Â Â Â Â LiabilitiesÂ Â Â Â Â Â Â Â Current assetsÂ Â Â Â Â Â Â Â Â Current liabilitiesÂ Â Â Â Â Â Â Â Cash and cash equivalentsÂ Â 157,729Â Â Â 241,133Â Â Loans and borrowingsÂ Â 516,417Â Â Â 385,300Â Trade accounts receivableÂ Â 976,381Â Â Â 860,916Â Â Lease liabilitiesÂ Â 31,363Â Â Â 31,867Â Other assetsÂ Â 231,284Â Â Â 222,728Â Â Trade accounts payableÂ Â 843,101Â Â Â 749,349Â InventoriesÂ Â 123,058Â Â Â 130,521Â Â Other accounts payableÂ Â 485,238Â Â Â 463,600Â Derivative financial instrumentsÂ Â â€"Â Â Â Â Â 721Â Â ProvisionsÂ Â 16,677Â Â Â 19,074Â Other investmentsÂ Â 102,292Â Â Â 93,132Â Â Insurance contract liabilitiesÂ Â 44,702Â Â Â 39,853Â Total current assetsÂ Â 1,590,744Â Â Â 1,549,151Â Â Deferred incomeÂ Â 204Â Â Â 267Â Â Â Â Â Â Â Â Â Â Â Total current liabilitiesÂ Â 1,937,702Â Â Â 1,689,310Â Non-current assetsÂ Â Â Â Â Â Â Â Â Â Â Â Â Â Â

Â Â Â Trade accounts receivableÂ Â 512Â Â Â 420Â Â Non-current liabilitiesÂ Â Â Â Â Â Â Â Other assetsÂ
Â 22,592Â Â Â 21,573Â Â Loans and borrowingsÂ Â 3,263,415Â Â Â 3,376,282Â Investments in associates and joint
ventureÂ Â 22,261Â Â Â 20,584Â Â Lease liabilitiesÂ Â 115,821Â Â Â 126,178Â Other investmentsÂ Â 282Â Â
Â 289Â Â Trade accounts payableÂ Â 3,599Â Â Â 3,906Â Property, furniture, and equipmentÂ Â 2,469,691Â Â
Â 2,573,140Â Â Other accounts payableÂ Â 87,780Â Â Â 221,132Â Intangible assetsÂ Â 2,984,030Â Â
Â 3,129,187Â Â Deferred tax liabilitiesÂ Â 406,977Â Â Â 495,826Â Right-of-use assetsÂ Â 127,768Â Â Â 139,386Â Â
Deferred incomeÂ Â 252Â Â Â 352Â Investment propertiesÂ Â 6,662Â Â Â 6,959Â Â Derivative financial
instrumentsÂ Â 42,218Â Â Â â€”Â Â Â Derivative financial instrumentsÂ Â 66,491Â Â Â 81,492Â Â Total non-current
liabilitiesÂ Â 3,920,062Â Â Â 4,223,676Â Deferred tax assetsÂ Â 201,457Â Â Â 167,371Â Â Total liabilitiesÂ
Â 5,857,764Â Â Â 5,912,986Â Total non-current assetsÂ Â 5,901,746Â Â Â 6,140,401Â Â Â Â Â Â Â Â Â Â Â Â Â
Â Â Â Â Â Â Â Â EquityÂ Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Share capitalÂ Â 17,385Â Â Â 8,820Â Â Â Â Â Â Â
Â Â Â Â Share premiumÂ Â 1,207,515Â Â Â â€”Â Â Â Â Â Â Â Â Â Â Â Â Â ReservesÂ Â 631,128Â Â Â 1,823,364Â
Â Â Â Â Â Â Â Â Â Â Retained lossesÂ Â (375,914)Â Â (366,899) Â Â Â Â Â Â Â Â Â Â Equity attributable to the
owner of the CompanyÂ Â 1,480,114Â Â Â 1,465,285Â Â Â Â Â Â Â Â Â Â Â Non-controlling interestÂ Â 154,612Â Â
Â 311,281Â Â Â Â Â Â Â Â Â Â Â Total equityÂ Â 1,634,726Â Â Â 1,776,566Â Total assetsÂ Â 7,492,490Â Â
Â 7,689,552Â Â Total liabilities and equityÂ Â 7,492,490Â Â Â 7,689,552Â Â 1Â Â Auna S.A. and Subsidiaries
Condensed Consolidated Interim Statement of Income and Other Comprehensive Income (Loss) For the three and six
months ended June 30, 2024 and 2023 Â Â Â Three-month period ended June 30 Six-month period ended June 30 In
thousands of solesÂ 2024Â 2023Â 2024Â 2023 RevenueÂ Â Â Â Â Â Â Â Insurance revenueÂ Â 256,336Â Â
Â 177,858Â Â Â 508,532Â Â Â 391,584Â Healthcare services revenueÂ Â 784,082Â Â Â 702,499Â Â Â 1,535,260Â Â
Â 1,320,246Â Sale of medicinesÂ Â 80,066Â Â Â 65,529Â Â Â 152,721Â Â Â 128,002Â Total revenue from contracts
with customersÂ Â 1,120,484Â Â Â 945,886Â Â Â 2,196,513Â Â Â 1,839,832Â Cost of sales and servicesÂ
Â (693,124)Â Â (586,183)Â Â (1,354,758)Â Â (1,152,218) Gross profitÂ Â 427,360Â Â Â 359,703Â Â Â 841,755Â Â
Â 687,614Â Selling expensesÂ Â (47,652)Â Â (51,108)Â Â (100,903)Â Â (96,771) Administrative expensesÂ
Â (201,559)Â Â (191,489)Â Â (392,486)Â Â (335,461) Loss for impairment of trade receivablesÂ Â (3,031)Â
Â (1,615)Â Â (2,835)Â Â (2,775) Other incomeÂ Â 7,600Â Â Â 20,371Â Â Â 19,064Â Â Â 27,999Â Operating profitÂ
Â 182,718Â Â Â 135,862Â Â Â 364,595Â Â Â 280,606Â Finance incomeÂ Â 6,580Â Â Â 33,090Â Â Â 15,319Â Â
Â 50,825Â Finance costsÂ Â (188,700)Â Â (128,844)Â Â (365,375)Â Â (268,239) Net finance costÂ Â (182,120)Â
Â (95,754)Â Â (350,056)Â Â (217,414) Share of profit of equity-accounted investeesÂ Â 2,277Â Â Â 1,669Â Â
Â 4,516Â Â Â 2,831Â Profit before taxÂ Â 2,875Â Â Â 41,777Â Â Â 19,055Â Â Â 66,023Â Â Income tax expenseÂ
Â 5,049Â Â Â (19,276)Â Â (19,467)Â Â (43,392) (Loss) profit for the periodÂ Â 7,924Â Â Â 22,501Â Â Â (412)Â
Â 22,631Â Other comprehensive lossÂ Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Items that are or may be reclassified
subsequently to profit or lossÂ Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Cash flow hedgesÂ Â (6,543)Â Â 41,995Â Â
Â (15,921)Â Â 41,652Â Foreign operations â€“ foreign currency translation differencesÂ Â (164,986)Â Â 94,759Â Â
Â (116,174)Â Â 205,641Â Equity-accounted investees â€“ share of OCIÂ Â â€”Â Â Â Â Â 39Â Â Â â€”Â Â Â Â
Â â€”Â Â Â Changes in fair value of Put and Call liabilityÂ Â 2,405Â Â Â 49,748Â Â Â â€”Â Â Â Â Â 45,724Â Other
investments at FVOCI â€“ net change in fair valueÂ Â 559Â Â Â â€”Â Â Â Â Â 559Â Â Â â€”Â Â Â Income tax
(expense) benefitÂ Â 1,321Â Â Â (12,493)Â Â 3,308Â Â Â (12,392) Other comprehensive (loss) income for the period,
net of taxÂ Â (167,244)Â Â 174,048Â Â Â (128,228)Â Â 280,625Â Total comprehensive (loss) income for the periodÂ
Â (159,320)Â Â 196,549Â Â Â (128,640)Â Â 303,256Â (Loss) income attributable to:Â Â Â Â Â Â Â Â Â Â Â Â Â
Â Â Â Owner of the CompanyÂ Â 3,753Â Â Â 1,747Â Â Â (9,582)Â Â (2,077) Non-controlling interestÂ Â 4,171Â Â
Â 20,754Â Â Â 9,170Â Â Â 24,708Â Â Â Â 7,924Â Â Â 22,501Â Â Â (412)Â Â 22,631Â Total comprehensive (loss)
income attributable to:Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Owner of the CompanyÂ Â (155,205)Â Â 119,548Â Â
Â (131,881)Â Â 218,786Â Non-controlling interestÂ Â (4,115)Â Â 77,001Â Â Â 3,241Â Â Â 84,470Â Â Â
Â (159,320)Â Â 196,549Â Â Â (128,640)Â Â 303,256Â Earnings per shareÂ Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Basic
and diluted earnings per shareÂ Â 0.05Â Â Â 0.04Â Â Â (0.16)Â Â (0.05) Â 2Â Â Auna S.A. and Subsidiaries
Condensed Consolidated Interim Statement of Changes in Equity For the six months ended June 30, 2024 and 2023 Â
Â Â Â Â Â Â Equity attributable to the owner of the CompanyÂ Â Â Â Â Â In thousands of solesÂ Share capitalÂ
Share premiumÂ Other capital reserveÂ Translation reserveÂ Cost of hedging reserveÂ Hedging reserveÂ Fair value
reserveÂ Merger and other reservesÂ Retained (losses) earningsÂ TotalÂ Non- controlling interestÂ Total equity
Balances as of December 31, 2022Â Â 236,547Â Â Â 386,045Â Â Â 56,314Â Â Â (190,389)Â Â (15,133)Â Â (16,756)Â
Â â€”Â Â Â Â Â 699,333Â Â Â (90,982)Â Â 1,064,979Â Â Â 493,082Â Â Â 1,558,061Â Balances as of January 1,
2023Â Â 236,547Â Â Â 386,045Â Â Â 56,314Â Â Â (190,389)Â Â (15,133)Â Â (16,756)Â Â â€”Â Â Â Â Â 699,333Â Â
Â (90,982)Â Â 1,064,979Â Â Â 493,082Â Â Â 1,558,061Â Profit for the periodÂ Â â€”Â Â Â Â Â â€”Â Â Â Â
Â â€”Â Â Â Â Â â€”Â Â Â Â Â â€”Â Â Â Â Â â€”Â Â Â Â Â â€”Â Â Â Â Â â€”Â Â Â Â Â (2,077)Â Â (2,077)Â
Â 24,708Â Â Â 22,631Â Other comprehensive income for the periodÂ Â â€”Â Â Â Â Â â€”Â Â Â Â Â â€”Â Â Â Â
Â 158,688Â Â Â (29,802)Â Â 55,946Â Â Â â€”Â Â Â Â Â 36,031Â Â Â â€”Â Â Â Â Â 220,863Â Â Â 59,762Â Â
Â 280,625Â Total comprehensive income for the periodÂ Â â€”Â Â Â Â Â â€”Â Â Â Â Â â€”Â Â Â Â Â 158,688Â Â
Â (29,802)Â Â 55,946Â Â Â â€”Â Â Â Â Â 36,031Â Â Â (2,077)Â Â 218,786Â Â Â 84,470Â Â Â 303,256Â Dividend
distributionÂ Â â€”Â Â Â Â Â â€”Â Â Â Â Â â€”Â Â Â Â Â â€”Â Â Â Â Â â€”Â Â Â Â Â â€”Â Â Â Â Â â€”Â Â Â Â
Â â€”Â Â Â Â Â â€”Â Â Â Â Â â€”Â Â Â Â Â (6,841)Â Â (6,841) Transfer to legal reserveÂ Â â€”Â Â Â Â Â â€”Â Â Â Â
Â 16,807Â Â Â â€”Â Â Â Â Â â€”Â Â Â Â Â â€”Â Â Â Â Â â€”Â Â Â Â Â â€”Â Â Â Â Â (16,807)Â Â â€”Â Â Â Â
Â â€”Â Â Â Â Â â€”Â Â Â Contributions from non-controlling ShareholdersÂ Â â€”Â Â Â Â Â â€”Â Â Â Â Â â€”Â Â Â Â
Â â€”Â Â Â Â Â â€”Â Â Â Â Â â€”Â Â Â Â Â â€”Â Â Â Â Â (1,016)Â Â â€”Â Â Â Â Â (1,016)Â Â 1,032Â Â Â 16Â Total
transactions with the owner of the CompanyÂ Â â€”Â Â Â Â Â â€”Â Â Â Â Â 16,807Â Â Â â€”Â Â Â Â Â â€”Â Â Â Â
Â â€”Â Â Â Â Â â€”Â Â Â Â Â (1,016)Â Â (16,807)Â Â (1,016)Â Â (5,809)Â Â (6,825) Balances as of June 30, 2023Â
Â 236,547Â Â Â 386,045Â Â Â 73,121Â Â Â (31,701)Â Â (44,935)Â Â 39,190Â Â Â â€”Â Â Â Â Â 734,348Â Â
Â (109,866)Â Â 1,282,749Â Â Â 571,743Â Â Â 1,854,492Â Balances as of December 31, 2023Â Â 8,820Â Â
Â â€”Â Â Â Â Â 79,782Â Â Â 140,066Â Â Â 6,422Â Â Â (29,548)Â Â 231Â Â Â 1,626,411Â Â Â (366,899)Â
Â 1,465,285Â Â Â 311,281Â Â Â 1,776,566Â Loss for the periodÂ Â â€”Â Â Â Â Â â€”Â Â Â Â Â â€”Â Â Â Â
Â â€”Â Â Â Â Â â€”Â Â Â Â Â â€”Â Â Â Â Â â€”Â Â Â Â Â â€”Â Â Â Â Â (9,582)Â Â (9,582)Â Â 9,170Â Â Â (412)
Other comprehensive loss for the periodÂ Â â€”Â Â Â Â Â â€”Â Â Â Â Â â€”Â Â Â Â Â (110,245)Â Â 7,653Â Â
Â (20,266)Â Â 559Â Â Â â€”Â Â Â Â Â â€”Â Â Â Â Â (122,299)Â Â (5,929)Â Â (128,228) Total comprehensive loss for
the periodÂ Â â€”Â Â Â Â Â â€”Â Â Â Â Â â€”Â Â Â Â Â (110,245)Â Â 7,653Â Â Â (20,266)Â Â 559Â Â Â â€”Â Â Â Â
Â (9,582)Â Â (131,881)Â Â 3,241Â Â Â (128,640) Issuance of common stock, net of issuance costsÂ Â 1,112Â Â

Â 1,207,515Â Â Â â€”Â Â Â Â Â â€”Â Â Â Â Â â€”Â Â Â Â Â â€”Â Â Â Â Â â€”Â Â Â Â Â â€”Â Â Â Â Â â€”Â Â Â Â Â 1,208,627Â Â Â â€”Â Â Â Â Â 1,208,627Â Capitalization of merger reserveÂ Â 7,453Â Â Â â€”Â Â Â Â Â â€”Â Â Â Â Â â€”Â Â Â Â Â â€”Â Â Â Â Â â€”Â Â Â Â Â â€”Â Â Â Â Â (7,453)Â Â â€”Â Â Â Â Â â€”Â Â Â Â Â â€”Â Â Â Â Â â€”Â Â Â Acquisition of non-controlling interestÂ Â â€”Â Â Â Â Â â€”Â Â Â Â Â â€”Â Â Â Â Â 18,909Â Â Â â€”Â Â Â Â Â â€”Â Â Â Â Â â€”Â Â Â Â Â (1,076,628)Â Â â€”Â Â Â Â Â (1,057,719)Â Â (159,910)Â Â (1,217,629) Change in fair value of put and call liabilityÂ Â â€”Â Â Â Â Â â€”Â Â Â Â Â â€”Â Â Â Â Â â€”Â Â Â Â Â â€”Â Â Â Â Â â€”Â Â Â Â Â â€”Â Â Â Â Â (4,765)Â Â â€”Â Â Â Â Â (4,765)Â Â â€”Â Â Â Â Â (4,765) Equity-settled share-based paymentÂ Â â€”Â Â Â Â Â â€”Â Â Â Â Â â€”Â Â Â Â Â â€”Â Â Â Â Â â€”Â Â Â Â Â â€”Â Â Â Â Â â€”Â Â Â Â Â â€”Â Â Â Â Â 567Â Â Â 567Â Â Â â€”Â Â Â Â Â 567Â Total transactions with the owner of the CompanyÂ Â 8,565Â Â Â 1,207,515Â Â Â â€”Â Â Â Â Â 18,909Â Â Â â€”Â Â Â Â Â â€”Â Â Â Â Â â€”Â Â Â Â Â (1,088,846)Â Â 567Â Â Â 146,710Â Â Â (159,910)Â Â (13,200) Balances as of June 30, 2024Â Â 17,385Â Â Â 1,207,515Â Â Â 79,782Â Â Â 48,730Â Â Â 14,075Â Â Â (49,814)Â Â 790Â Â Â 537,565Â Â Â (375,914)Â Â 1,480,114Â Â Â 154,612Â Â Â 1,634,726Â Â Â 3Â Â Auna S.A. and Subsidiaries Condensed Consolidated Interim Statement of Cash Flows For the six months ended June 30, 2024 and 2023 Â Â Â Six-month period ended June 30 In thousands of solesÂ 2024Â 2023 Cash flows from operating activitiesÂ Â Â Â Â Â Â Â (Loss) profit for the periodÂ Â (412)Â Â 22,631Â Adjustments for:Â Â Â Â Â Â Â Â DepreciationÂ Â 59,840Â Â Â 70,239Â Depreciation of right-of-use assetsÂ Â 13,608Â Â Â 12,364Â AmortizationÂ Â 38,947Â Â Â 38,230Â (Reversal) Impairment of inventoriesÂ Â (2,194)Â Â (456) Equity-settled share-based payment transactionsÂ Â 567Â Â Â â€”Â Â Â Loss on disposal of property, furniture, and equipmentÂ Â 813Â Â Â 1,234Â Loss (Gain) on disposal of right-of-use assets net of leases liabilitiesÂ Â 60Â Â Â (6) Loss on disposal of intangiblesÂ Â 1,168Â Â Â 3Â Loss for impairment of trade receivablesÂ Â 2,835Â Â Â 2,775Â Share of profit of equity-accounted investeesÂ Â (4,516)Â Â (2,831) Technical provisions and other provisionsÂ Â 440Â Â Â 200Â Other income for reversal of contingent considerationÂ Â â€”Â Â Â Â Â (4,095) Finance incomeÂ Â (15,319)Â Â (50,825) Finance costsÂ Â 365,375Â Â Â 268,239Â Income tax expenseÂ Â 19,467Â Â Â 43,392Â Net changes in assets and liabilities:Â Â Â Â Â Â Â Â Trade accounts receivable and other assetsÂ Â (211,635)Â Â (130,329) InventoriesÂ Â 6,505Â Â Â 573Â Trade accounts payable and other accounts payableÂ Â 91,516Â Â Â 44,664Â ProvisionsÂ Â (2,146)Â Â (1,258) Insurance contract liabilitiesÂ Â 5,834Â Â Â 20,148Â Cash from operating activitiesÂ Â 370,753Â Â Â 334,892Â Income tax paidÂ Â (111,496)Â Â (73,296) Interest receivedÂ Â 12,137Â Â Â 7,186Â Net cash from operating activitiesÂ Â 271,394Â Â Â 268,782Â Cash flows from investing activitiesÂ Â Â Â Â Â Â Â Acquisition of subsidiary, net of cash acquiredÂ Â â€”Â Â Â Â Â (59,994) Purchase of properties, furniture, and equipmentÂ Â (34,880)Â Â (40,134) Proceeds from sale of property, furniture, and equipmentÂ Â 127Â Â Â 522Â Purchase of intangiblesÂ Â (22,010)Â Â (14,676) Dividends from equity-accounted investeesÂ Â 622Â Â Â â€”Â Â Â Other assets (Trust funds)Â Â â€”Â Â Â Â Â 94,539Â Purchase of other investmentsÂ Â (12,819)Â Â (14,691) Proceeds from advance payment for purchase of sharesÂ Â â€”Â Â Â Â Â 11,592Â Payment for contingent considerationÂ Â (46,991)Â Â (33,210) Net cash used in investing activitiesÂ Â (115,951)Â Â (56,052) Cash flows from financing activitiesÂ Â Â Â Â Â Â Â Proceeds from issuance of common stock in initial public offering, net of issuance costsÂ Â 1,267,794Â Â Â â€”Â Â Â Payments of initial public offering costsÂ Â (15,842)Â Â â€”Â Â Â Proceeds from loans and borrowingsÂ Â 474,540Â Â Â 2,261,000Â Payment of loans and borrowingsÂ Â (437,446)Â Â (2,111,504) Payment of lease liabilitiesÂ Â (22,607)Â Â (20,403) Payment for derivatives premiumsÂ Â (35,328)Â Â (15,044) Contributions from non-controlling shareholdersÂ Â â€”Â Â Â Â Â 16Â Payment for costs of Extinguishment of debtÂ Â (16,607)Â Â â€”Â Â Â Interest paidÂ Â (229,067)Â Â (253,325) Dividend paidÂ Â â€”Â Â Â Â Â (6,841) Acquisition of non-controlling interestÂ Â (1,217,629)Â Â â€”Â Â Â Net cash used in financing activitiesÂ Â (232,192)Â Â (146,101) Net (decrease) increase in cash and cash equivalentsÂ Â (76,749)Â Â 66,629Â Cash and cash equivalents at January 1Â Â 241,133Â Â Â 208,694Â Exchange difference on cash and cash equivalents for the periodÂ Â (6,655)Â Â (16,537) Cash and cash equivalents at June 30Â Â 157,729Â Â Â 258,786Â Transactions not representing cash flowsÂ Â Â Â Â Â Â Â Assets acquired through finance lease and other financingÂ Â 4,653Â Â Â 4,601Â Assets acquired from suppliers in installmentsÂ Â 137Â Â Â 9,470Â Â 4Â Â Auna S.A. and Subsidiaries Notes to the Condensed Consolidated Interim Financial Statements June 30, 2024 Â Operating SegmentsÂ A.Basis for segmentation Â The Group has determined four reportable segments.These operating segments are components of a company about which separate financial information is available that is regularly evaluatedby the Board of Directors (Chief operating decision maker) in deciding how to allocate resources and assess performance.Â The following summary describes the operationsof each reportable segment.Â Reportable segments Operations Oncosalud Peru Including our prepaidÂ oncologic healthcare plans and healthcare servicesÂ related to the treatment of cancer. Healthcare services in Peru Corresponds to medical services within the network of clinics and health centers in Peru. Healthcare services in Colombia Corresponds to medical servicesÂ within the network of clinics and health centers in Colombia. Healthcare services in Mexico Corresponds to medical services within the network of clinics and health centers, and the insurance business in Mexico. Â B.Information about reportable segmentsÂ Information related to each reportable segmentis set out below. Segment profit (loss) before tax is used to measure performance because the chief operating decision maker believesthat this information is the most relevant for the Group.Â 5Â Â Auna S.A. and Subsidiaries Notes to the Condensed Consolidated Interim Financial Statements June 30, 2024Â For the three months period ended June 30, 2024:Â Â Â Reportable segments In thousands of solesÂ OncosaludPeruÂ Healthcare services in PeruÂ Healthcare services in ColombiaÂ Healthcare services in MexicoÂ Total reportable segmentsÂ Holding and eliminationsÂ Total 2024Â Â Â Â Â Â Â Â Â Â Â Â Â Â External revenuesÂ Â 257,589Â Â Â 182,916Â Â Â 377,624Â Â Â 302,355Â Â Â 1,120,484Â Â Â â€”Â Â Â Â Â 1,120,484Â Inter-segment revenue (i)Â Â 10,952Â Â Â 72,077Â Â Â â€”Â Â Â Â Â â€”Â Â Â Â Â 83,029Â Â Â (83,029)Â Â â€”Â Â Â Segment revenueÂ Â 268,541Â Â Â 254,993Â Â Â 377,624Â Â Â 302,355Â Â Â 1,203,513Â Â Â (83,029)Â Â 1,120,484Â External cost of serviceÂ Â (78,814)Â Â (170,403)Â Â (273,191)Â Â (170,716)Â Â (693,124)Â Â â€”Â Â Â Â Â (693,124) Inter-segment cost of service (i)Â Â (72,215)Â Â (10,313)Â Â â€”Â Â Â Â Â â€”Â Â Â Â Â (82,528)Â Â 82,528Â Â Â â€”Â Â Â Segment cost of serviceÂ Â (151,029)Â Â (180,716)Â Â (273,191)Â Â (170,716)Â Â (775,652)Â Â 82,528Â Â Â (693,124) Gross profitÂ Â 117,512Â Â Â 74,277Â Â Â 104,433Â Â Â 131,639Â Â Â 427,861Â Â Â (501)Â Â 427,360Â External selling expensesÂ Â (40,099)Â Â (5,688)Â Â (1,583)Â Â 18Â Â Â (47,352)Â Â (300)Â Â (47,652) Segment selling expensesÂ Â (40,099)Â Â (5,688)Â Â (1,583)Â Â 18Â Â Â (47,352)Â Â (300)Â Â (47,652) External administrative expensesÂ Â (19,522)Â Â (25,563)Â Â (52,312)Â Â (63,039)Â Â (160,436)Â Â â€”Â Â Â Â Â (160,436) Inter-segment administrative expensesÂ Â (94)Â Â (2,238)Â Â â€”Â Â Â Â Â â€”Â Â Â Â Â (2,332)Â Â 2,332Â Â Â â€”Â Â Â Corporate expensesÂ Â (17,493)Â Â (14,908)Â Â (2,953)Â Â (2,232)Â Â (37,586)Â Â (3,537)Â Â (41,123) Segment administrative expensesÂ Â (37,109)Â

Â (42,709)Â Â (55,265)Â Â (65,271)Â Â (200,354)Â Â (1,205)Â Â (201,559) Impairment losses on trade receivablesÂ
Â 17Â Â Â 162Â Â Â (2,995)Â Â (210)Â Â (3,026)Â Â (5)Â Â (3,031) Other incomeÂ Â 591Â Â Â 1,324Â Â
Â 1,094Â Â Â 4,342Â Â Â 7,351Â Â Â 249Â Â Â 7,600Â Inter-segment other incomeÂ Â 3,773Â Â Â 496Â Â
Â â€”Â Â Â Â Â â€”Â Â Â Â Â 4,269Â Â Â (4,269)Â Â â€”Â Â Â Other incomeÂ Â 4,364Â Â Â 1,820Â Â Â 1,094Â Â
Â 4,342Â Â Â 11,620Â Â Â (4,020)Â Â 7,600Â Segment operating profit (loss)Â Â 44,685Â Â Â 27,862Â Â
Â 45,684Â Â Â 70,518Â Â Â 188,749Â Â Â (6,031)Â Â 182,718Â Share of profit of equity accounted investees, net of
taxesÂ Â 930Â Â Â â€”Â Â Â Â Â 1,347Â Â Â â€”Â Â Â Â Â 2,277Â Â Â â€”Â Â Â Â Â 2,277Â Exchange difference,
netÂ Â 173Â Â Â (3,733)Â Â (36,485)Â Â (19,005)Â Â (59,050)Â Â 9,557Â Â Â (49,493) Interest expense, netÂ
Â (4,206)Â Â (11,635)Â Â (28,301)Â Â (62,039)Â Â (106,181)Â Â (26,446)Â Â (132,627) Segment profit (loss) before
taxÂ Â 41,582Â Â Â 12,494Â Â Â (17,755)Â Â (10,526)Â Â 25,795Â Â Â (22,920)Â Â 2,875Â Other disclosuresÂ
Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Depreciation and amortizationÂ Â (7,956)Â Â (10,473)Â
Â (10,828)Â Â (24,504)Â Â (53,761)Â Â (2,200)Â Â (55,961) Capital expenditureÂ Â (4,416)Â Â (9,278)Â
Â (12,863)Â Â (6,301)Â Â (32,858)Â Â (3,069)Â Â (35,927) Segment assetsÂ Â 52,473Â Â Â 59,213Â Â Â (103,508)Â
Â (358,346)Â Â (350,168)Â Â (57,748)Â Â (407,916) Segment liabilitiesÂ Â 24,482Â Â Â 51,944Â Â Â (56,140)Â
Â (186,564)Â Â (166,278)Â Â (76,860)Â Â (243,138) Â 6Â Â Auna S.A. and Subsidiaries Notes to the Condensed
Consolidated Interim Financial Statements June 30, 2024Â For the three months period ended June 30, 2023:Â Â Â
Reportable segments In thousands of solesÂ OncosaludPeruÂ Healthcare services in PeruÂ Healthcare services in
ColombiaÂ Healthcare services in MexicoÂ Total reportable segmentsÂ Holding and eliminationsÂ Total 2023Â Â Â
Â Â Â Â Â Â Â Â Â Â Â External revenuesÂ Â 219,846Â Â Â 163,205Â Â Â 281,521Â Â Â 281,314Â Â
Â 945,886Â Â Â â€”Â Â Â Â Â 945,886Â Inter-segment revenue (i)Â Â 10,257Â Â Â 53,561Â Â Â â€”Â Â Â Â
Â â€”Â Â Â Â Â 63,818Â Â Â (63,818)Â Â â€”Â Â Â Segment revenueÂ Â 230,103Â Â Â 216,766Â Â Â 281,521Â Â
Â 281,314Â Â Â 1,009,704Â Â Â (63,818)Â Â 945,886Â External cost of serviceÂ Â (66,432)Â Â (160,121)Â
Â (203,026)Â Â (156,604)Â Â (586,183)Â Â â€”Â Â Â Â Â (586,183) Inter-segment cost of service (i)Â Â (52,854)Â
Â (9,104)Â Â â€”Â Â Â Â Â â€”Â Â Â Â Â (61,958)Â Â 61,958Â Â Â â€”Â Â Â Segment cost of serviceÂ Â (119,286)Â
Â (169,225)Â Â (203,026)Â Â (156,604)Â Â (648,141)Â Â 61,958Â Â Â (586,183) Gross profitÂ Â 110,817Â Â
Â 47,541Â Â Â 78,495Â Â Â 124,710Â Â Â 361,563Â Â Â (1,860)Â Â 359,703Â External selling expensesÂ
Â (42,035)Â Â (4,426)Â Â (1,598)Â Â (2,893)Â Â (50,952)Â Â (156)Â Â (51,108) Segment selling expensesÂ
Â (42,035)Â Â (4,426)Â Â (1,598)Â Â (2,893)Â Â (50,952)Â Â (156)Â Â (51,108) External administrative expensesÂ
Â (19,516)Â Â (24,889)Â Â (46,382)Â Â (58,525)Â Â (149,312)Â Â â€”Â Â Â Â Â (149,312) Inter-segment
administrative expensesÂ Â (230)Â Â (1,540)Â Â â€”Â Â Â Â Â â€”Â Â Â Â Â (1,770)Â Â 1,770Â Â Â â€”Â Â Â
Corporate expensesÂ Â (21,954)Â Â (19,053)Â Â (1,473)Â Â â€”Â Â Â Â Â (42,480)Â Â 303Â Â Â (42,177) Segment
administrative expensesÂ Â (41,700)Â Â (45,482)Â Â (47,855)Â Â (58,525)Â Â (193,562)Â Â 2,073Â Â Â (191,489)
Impairment losses on trade receivablesÂ Â 232Â Â Â (230)Â Â (1,140)Â Â (406)Â Â (1,544)Â Â (71)Â Â (1,615) Other
expensesÂ Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Other incomeÂ Â 379Â Â Â 1,702Â Â
Â 11,642Â Â Â 6,648Â Â Â 20,371Â Â Â â€”Â Â Â Â Â 20,371Â Inter-segment other incomeÂ Â 2,765Â Â Â 287Â Â
Â â€”Â Â Â Â Â â€”Â Â Â Â Â 3,052Â Â Â (3,052)Â Â â€”Â Â Â Other incomeÂ Â 3,144Â Â Â 1,989Â Â Â 11,642Â Â
Â 6,648Â Â Â 23,423Â Â Â (3,052)Â Â 20,371Â Segment operating profit (loss)Â Â 30,458Â Â Â (608)Â Â 39,544Â Â
Â 69,534Â Â Â 138,928Â Â Â (3,066)Â Â 135,862Â Share of profit of equity accounted investees, net of taxesÂ
Â 581Â Â Â â€”Â Â Â Â Â 1,088Â Â Â â€”Â Â Â Â Â 1,669Â Â Â â€”Â Â Â Â Â 1,669Â Exchange difference, netÂ
Â 1,996Â Â Â 1,222Â Â Â 53,943Â Â Â 14,448Â Â Â 71,609Â Â Â (41,647)Â Â 29,962Â Interest expense, netÂ
Â (5,767)Â Â (11,167)Â Â (22,037)Â Â (63,568)Â Â (102,539)Â Â (23,177)Â Â (125,716) Segment profit (loss) before
taxÂ Â 27,268Â Â Â (10,553)Â Â 72,538Â Â Â 20,414Â Â Â 109,667Â Â Â (67,890)Â Â 41,777Â Other disclosuresÂ
Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Depreciation and amortizationÂ Â (7,231)Â Â (10,144)Â
Â (9,844)Â Â (26,843)Â Â (54,062)Â Â (2,267)Â Â (56,329) Capital expenditureÂ Â (4,820)Â Â (5,200)Â Â (16,161)Â
Â 7,849Â Â Â (18,332)Â Â (2,736)Â Â (21,068) Segment assetsÂ Â 31,027Â Â Â 27,362Â Â Â 188,459Â Â
Â 92,852Â Â Â 339,700Â Â Â (232,060)Â Â 107,640Â Segment liabilitiesÂ Â (46,528)Â Â 32,042Â Â Â (34,811)Â
Â 51,991Â Â Â 2,694Â Â Â (142,290)Â Â (139,596) Â 7Â Â Auna S.A. and Subsidiaries Notes to the Condensed
Consolidated Interim Financial Statements June 30, 2024Â For the six months period ended June 30, 2024:Â Â Â Â
Reportable segments In thousands of solesÂ OncosaludPeruÂ Healthcare services in PeruÂ Healthcare services in
ColombiaÂ Healthcare services in MexicoÂ Total reportable segmentsÂ Holding and eliminationsÂ Total 2024Â Â Â
Â Â Â Â Â Â Â Â Â Â Â External revenuesÂ Â 502,430Â Â Â 356,775Â Â Â 726,510Â Â Â 610,798Â Â
Â 2,196,513Â Â Â â€”Â Â Â Â Â 2,196,513Â Inter-segment revenue (i)Â Â 19,547Â Â Â 139,144Â Â Â â€”Â Â Â Â
Â â€”Â Â Â Â Â 158,691Â Â Â (158,691)Â Â â€”Â Â Â Segment revenueÂ Â 521,977Â Â Â 495,919Â Â Â 726,510Â Â
Â 610,798Â Â Â 2,355,204Â Â Â (158,691)Â Â 2,196,513Â External cost of serviceÂ Â (154,523)Â Â (332,413)Â
Â (533,038)Â Â (334,784)Â Â (1,354,758)Â Â â€”Â Â Â Â Â (1,354,758) Inter-segment cost of service (i)Â
Â (139,406)Â Â (18,283)Â Â â€”Â Â Â Â Â â€”Â Â Â Â Â (157,689)Â Â 157,689Â Â Â â€”Â Â Â Segment cost of
serviceÂ Â (293,929)Â Â (350,696)Â Â (533,038)Â Â (334,784)Â Â (1,512,447)Â Â 157,689Â Â Â (1,354,758) Gross
profitÂ Â 228,048Â Â Â 145,223Â Â Â 193,472Â Â Â 276,014Â Â Â 842,757Â Â Â (1,002)Â Â 841,755Â External
selling expensesÂ Â (81,247)Â Â (10,200)Â Â (3,314)Â Â (5,682)Â Â (100,443)Â Â (460)Â Â (100,903) Segment
selling expensesÂ Â (81,247)Â Â (10,200)Â Â (3,314)Â Â (5,682)Â Â (100,443)Â Â (460)Â Â (100,903) External
administrative expensesÂ Â (36,971)Â Â (51,233)Â Â (100,602)Â Â (129,450)Â Â (318,256)Â Â â€”Â Â Â Â
Â (318,256) Inter-segment administrative expensesÂ Â (171)Â Â (2,737)Â Â â€”Â Â Â Â Â â€”Â Â Â Â Â (2,908)Â
Â 2,908Â Â Â â€”Â Â Â Corporate expensesÂ Â (32,333)Â Â (29,984)Â Â (5,905)Â Â (4,462)Â Â (72,684)Â
Â (1,546)Â Â (74,230) Segment administrative expensesÂ Â (69,475)Â Â (83,954)Â Â (106,507)Â Â (133,912)Â
Â (393,848)Â Â 1,362Â Â Â (392,486) Impairment losses on trade receivablesÂ Â 102Â Â Â 404Â Â Â (2,998)Â
Â (415)Â Â (2,907)Â Â 72Â Â Â (2,835) Other incomeÂ Â 1,191Â Â Â 2,807Â Â Â 2,778Â Â Â 12,439Â Â
Â 19,215Â Â Â (151)Â Â 19,064Â Inter-segment other incomeÂ Â 5,505Â Â Â 501Â Â Â â€”Â Â Â Â Â â€”Â Â Â Â
Â 6,006Â Â Â (6,006)Â Â â€”Â Â Â Other incomeÂ Â 6,696Â Â Â 3,308Â Â Â 2,778Â Â Â 12,439Â Â Â 25,221Â Â
Â (6,157)Â Â 19,064Â Segment operating profit (loss)Â Â 84,124Â Â Â 54,781Â Â Â 83,431Â Â Â 148,444Â Â
Â 370,780Â Â Â (6,185)Â Â 364,595Â Share of profit of equity accounted investees, net of taxesÂ Â 1,943Â Â
Â â€”Â Â Â Â Â 2,573Â Â Â â€”Â Â Â Â Â 4,516Â Â Â â€”Â Â Â Â Â 4,516Â Exchange difference, netÂ Â (1,432)Â
Â (5,155)Â Â (37,707)Â Â (12,206)Â Â (56,500)Â Â 9,921Â Â Â (46,579) Interest expense, netÂ Â (10,448)Â
Â (23,171)Â Â (57,786)Â Â (158,310)Â Â (249,715)Â Â (53,762)Â Â (303,477) Segment profit (loss) before taxÂ
Â 74,187Â Â Â 26,455Â Â Â (9,489)Â Â (22,072)Â Â 69,081Â Â Â (50,026)Â Â 19,055Â Other disclosuresÂ Â Â Â Â
Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Depreciation and amortizationÂ Â (15,764)Â Â (20,713)Â

Â (21,499)Â Â (50,067)Â Â (108,043)Â Â (4,352)Â Â (112,395) Capital expenditureÂ Â (7,946)Â Â (15,844)Â Â (21,862)Â Â (10,408)Â Â (56,060)Â Â (5,620)Â Â (61,680) Segment assetsÂ Â 2,200,846Â Â Â 970,690Â Â Â 2,372,301Â Â Â 3,508,279Â Â Â 9,052,116Â Â Â (1,559,626)Â Â 7,492,490Â Segment liabilitiesÂ Â 1,107,415Â Â Â 629,106Â Â Â 1,488,024Â Â Â 2,239,121Â Â Â 5,463,666Â Â Â 394,098Â Â Â 5,857,764Â Â 8Â Â Auna S.A. and Subsidiaries Notes to the Condensed Consolidated Interim Financial Statements June 30, 2024Â For the six months period ended June 30, 2023:Â Â Â Reportable segments In thousands of solesÂ OncosaludPeruÂ Healthcare services in PeruÂ Healthcare services in ColombiaÂ Healthcare services in MexicoÂ Total reportable segmentsÂ Holding and eliminationsÂ Total 2023Â Â Â Â Â Â Â Â Â Â Â Â Â Â External revenuesÂ Â 431,608Â Â Â 322,188Â Â Â 533,812Â Â Â 552,224Â Â Â 1,839,832Â Â Â â€”Â Â Â Â Â 1,839,832Â Inter-segment revenue (i)Â Â 19,104Â Â Â 106,590Â Â Â â€”Â Â Â Â Â â€”Â Â Â Â Â 125,694Â Â Â (125,694)Â Â â€”Â Â Â Segment revenueÂ Â 450,712Â Â Â 428,778Â Â Â 533,812Â Â Â 552,224Â Â Â 1,965,526Â Â Â (125,694)Â Â 1,839,832Â External cost of serviceÂ Â (134,614)Â Â (313,297)Â Â (384,414)Â Â (319,893)Â Â (1,152,218)Â Â â€”Â Â Â Â Â (1,152,218) Inter-segment cost of service (i)Â Â (105,862)Â Â (17,441)Â Â â€”Â Â Â Â Â â€”Â Â Â Â Â (123,303)Â Â 123,303Â Â Â â€”Â Â Â Segment cost of serviceÂ Â (240,476)Â Â (330,738)Â Â (384,414)Â Â (319,893)Â Â (1,275,521)Â Â 123,303Â Â Â (1,152,218) Gross profitÂ Â 210,236Â Â Â 98,040Â Â Â 149,398Â Â Â 232,331Â Â Â 690,005Â Â Â (2,391)Â Â 687,614Â External selling expensesÂ Â (79,581)Â Â (9,464)Â Â (2,928)Â Â (4,528)Â Â (96,501)Â Â (270)Â Â (96,771) Segment selling expensesÂ Â (79,581)Â Â (9,464)Â Â (2,928)Â Â (4,528)Â Â (96,501)Â Â (270)Â Â (96,771) External administrative expensesÂ Â (36,285)Â Â (45,743)Â Â (87,660)Â Â (92,392)Â Â (262,080)Â Â â€”Â Â Â Â Â (262,080) Inter-segment administrative expensesÂ Â (405)Â Â (2,676)Â Â â€”Â Â Â Â Â â€”Â Â Â Â Â (3,081)Â Â 3,081Â Â Â â€”Â Â Â Corporate expensesÂ Â (38,279)Â Â (33,220)Â Â (2,946)Â Â â€”Â Â Â Â Â (74,445)Â Â 1,064Â Â Â (73,381) Segment administrative expensesÂ Â (74,969)Â Â (81,639)Â Â (90,606)Â Â (92,392)Â Â (339,606)Â Â 4,145Â Â Â (335,461) Impairment losses on trade receivablesÂ Â 388Â Â Â 1,085Â Â Â (3,356)Â Â (767)Â Â (2,650)Â Â (125)Â Â (2,775) Other expensesÂ Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Other incomeÂ Â 518Â Â Â 2,580Â Â Â 12,876Â Â Â 12,024Â Â Â 27,998Â Â Â 1Â Â Â 27,999Â Inter-segment other incomeÂ Â 5,150Â Â Â 497Â Â Â â€”Â Â Â Â Â â€”Â Â Â Â Â 5,647Â Â Â (5,647)Â Â â€”Â Â Â Other incomeÂ Â 5,668Â Â Â 3,077Â Â Â 12,876Â Â Â 12,024Â Â Â 33,645Â Â Â (5,646)Â Â 27,999Â Segment operating profit (loss)Â Â 61,742Â Â Â 11,099Â Â Â 65,384Â Â Â 146,668Â Â Â 284,893Â Â Â (4,287)Â Â 280,606Â Share of profit of equity accounted investees, net of taxesÂ Â 1,047Â Â Â â€”Â Â Â Â Â 1,784Â Â Â â€”Â Â Â Â Â 2,831Â Â Â â€”Â Â Â Â Â 2,831Â Exchange difference, netÂ Â 1,476Â Â Â 1,723Â Â Â 76,365Â Â Â 17,556Â Â Â 97,120Â Â Â (53,858)Â Â 43,262Â Interest expense, netÂ Â (13,569)Â Â (20,942)Â Â (43,494)Â Â (136,623)Â Â (214,628)Â Â (46,048)Â Â (260,676) Segment profit (loss) before taxÂ Â 50,696Â Â Â (8,120)Â Â 100,039Â Â Â 27,601Â Â Â 170,216Â Â Â (104,193)Â Â 66,023Â Other disclosuresÂ Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Depreciation and amortizationÂ Â (14,524)Â Â (20,258)Â Â (18,865)Â Â (62,648)Â Â (116,295)Â Â (4,538)Â Â (120,833) Capital expenditureÂ Â (7,436)Â Â (7,141)Â Â (39,474)Â Â (10,197)Â Â (64,248)Â Â (4,633)Â Â (68,881) Segment assetsÂ Â 2,016,170Â Â Â 880,518Â Â Â 2,100,475Â Â Â 3,716,132Â Â Â 8,713,295Â Â Â (1,526,330)Â Â 7,186,965Â Segment liabilitiesÂ Â 982,079Â Â Â 593,995Â Â Â 1,363,770Â Â Â 2,272,997Â Â Â 5,212,841Â Â Â 119,632Â Â Â 5,332,473Â Â (i)Inter-segment cost of service (claims expense) from the Oncosalud Peru segment and intersegment revenue from our Healthcare Services in Peru segment are presented on a gross basis by adding the corresponding profit margin markup by our Healthcare Services in Peru segment and vice versa. Likewise, our Oncosalud Peru segment consolidates Oncocenter Peru S.A.C., a subsidiary providing healthcare services related to the exclusive treatment of cancer. In the separate financial statements of Oncocenter Peru S.A.C., the revenue mainly consists of the insurance claims expense recorded as cost of sales in the separate financial statements of Oncosalud S.A.C., our insurance subsidiary that is also consolidated in Oncosalud Peru segment. In the segment consolidation process the related revenues from such healthcare services are eliminated with the corresponding claims expense of our insurance subsidiary Oncosalud S.A.C., while the external cost (third parties) of services incurred by Oncocenter Peru S.A.C. remains.Â 9Â